A Phase 2 interventional study of GSK2894512 1% Cream and GSK2894512 0.5% Cream in Psoriasis, sponsored by GlaxoSmithKline. Completed at 46 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-11-13.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.
Among the 19 studies testing tapinarof in Psoriasis, this one is the 7th largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 3rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
Pakistan Institute of Medical Sciences · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6 · Phase 4 6
First in 2010; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 58 across the 19 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
26 studies in Psoriasis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 22 finished, 15 (68%) have results posted.
Among the 26 studies in Psoriasis by GlaxoSmithKline, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 2, and was the 20th registered.
GlaxoSmithKline’s Psoriasis studies by the year they started, since 2004.
1 of the studies testing tapinarof in Psoriasis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tapinarof in Psoriasis, from their registry updates:
Among GlaxoSmithKline’s 26 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in subjects with plaque psoriasis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and dosing frequency in future clinical safety and efficacy studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all psoriasis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adult males and females subjects with plaque psoriasis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NOTES: The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), with machine over-read. The QTc should be based on a single obtained over a brief recording period. If QTc is outside of the threshold value, triplicate ECGs may be performed with the QTc values averaged.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram \[mg/g\]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
Drug: GSK2894512 1% Cream
Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
Drug: GSK2894512 1% Cream
Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
Drug: GSK2894512 0.5% Cream
Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
Drug: GSK2894512 0.5% Cream
Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
Drug: Vehicle cream
Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
Drug: Vehicle cream
1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
White to off-white vehicle cream base to be applied topically
Percentage of Participants Who Have a Physician Global Assessment (PGA) Score of 0 or 1 at Week 12 and a Minimum 2-grade Improvement in PGA Score From Baseline to Week 12
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. The analysis was performed on modified intent-to-treat (mITT) Population which comprised of all randomized participants except those enrolled at center ID 220008.
Time frame: Baseline and up to Week 12
Percentage of Participants With >=75 Percent Improvement in Psoriasis Area and Severity Index (PASI) From Baseline to Each Study Visit
The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0 to 4) and the % BSA affected was scored on a 7-point scale (0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. Higher scores indicated more severe disease. The percentage of participants with \>=75% improvement in PASI from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
Percentage of Participants With a Minimum 2 Grade Improvement in PGA Score From Baseline to Each Study Visit
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a minimum 2-grade improvement from Baseline for each study visit were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
Percentage of Participants With a PGA Score of 0 or 1 at Each Study Visit
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a PGA score of 0 or 1 from Baseline at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 16
Mean Change in Percent of BSA Affected With Psoriasis From Baseline to Each Study Visit
The extent of BSA affected by psoriasis is a general indicator of disease severity and was measured throughout the study. The extent of BSA to which study treatment was applied was also recorded. For the purpose of approximate clinical estimation, the total palmar surface of the palm plus 5 digits was assumed to be approximately equivalent to 1 percent BSA. Assessment of BSA affected with psoriasis was performed separately for four body surface regions: the head, the upper extremities, the trunk and the lower extremities, corresponding to 10, 20, 30 and 40 percent of the total body area, respectively. The mean change in percent BSA affected from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
Mean Change in PASI Score From Baseline to Each Study Visit
The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of BSA affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0=None to 4=Severe) and the percent of BSA affected is scored on a 7-point scale (0=0% involvement to 6=90-100%) for each of 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. PASI score ranged from 0=no psoriasis to 72=worse psoriasis. The mean change in PASI score from Baseline was summarized for each study visit. Baseline was the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
PGA Scores at Each Study Visit
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean of PGA scores at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 16
Mean Change in PGA Score From Baseline to Each Study Visit
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean change in PGA scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
Mean Change in Individual Target Lesion Grading Scores From Baseline to Each Study Visit
A single target lesion of at least 3 centimeter (cm) x 3 cm was selected at Baseline. For the selected lesion, the severity of erythema, scaling and plaque thickness (induration) was assessed by the investigator on a 5-point scale ranging from 0=none to 4=severe. The mean change in individual grading scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
Mean Change in Weekly Average Itch/Pruritus Numeric Rating Scale (NRS) From Baseline to Each Study Visit
The participant reported itch severity was obtained from the response of the participants to the itch NRS item in the psoriasis symptom diary (PSD). PSD was developed to assess daily self-reports of psoriasis symptoms and the functional impact related to the underlying pathophysiology of the disease. The participants answered questions related to the severity and impact of the signs and symptoms daily using a 11 point NRS with scores ranging from 0 (absent) to 10 (worst imaginable). Mean change in itch/pruritis NRS from Baseline to each study visit was presented. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the post dose weekly average value minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
Percentage of Participants Who Achieved a PGA Score of 0 or 1 and a Minimum 2 Grade Improvement From Baseline to Each Study Visit
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from baseline were summarized. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 16
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. A TEAE is defined as an AE which occurred on or after study treatment start date and on or before the last visit. Number of participants with AEs and SAEs were presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.
Time frame: Up to Week 16
Number of Participants With Reported Local Tolerability Scores
The assessment of the presence and degree of burning/stinging and itching at the application site following application of the study treatment was done at each specified study visit using a 5 point tolerability scale. The scores ranged from 0 to 4 where 0=None and 4=Strong/Severe. The score represented an average across all application sites. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 14
Change From Baseline in Albumin and Protein Level
Blood samples were collected for the evaluation of change in albumin and protein levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Alkaline Phosphatase (Alk Phos), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma Glutamyl Transferase (GGT) Levels.
Blood samples were collected for the evaluation of change in levels of alk phos, ALT, AST and GGT from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Direct Bilirubin (Bil), Bilirubin (Bil), Creatinine and Urate.
Blood samples were collected for the evaluation of change in levels of direct bil, bil, creatinine and urate from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Calcium, Chloride, Carbon Dioxide (CO2), Glucose, Potassium, Sodium and Urea Levels
Blood samples were collected for the evaluation of change in levels of calcium, chloride, CO2, glucose, potassium, sodium, and urea from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocyte Count
Blood samples were collected for the evaluation of change in levels of basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Hematocrit Levels
Blood samples were collected for the evaluation of change in hematocrit levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Hemoglobin (Hgb) Level and Erythrocyte Mean Corpuscular Hgb Concentration (MCHC)
Blood samples were collected for the evaluation of change in Hgb levels and MCHC from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Level
Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular hemoglobin level from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular volume from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Erythrocyte Count
Blood samples were collected for the evaluation of change in erythrocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Number of Participants With Chemistry Data of Potential Clinical Importance
Blood samples were collected for the evaluation of clinical chemistry parameters including alk phos, ALT, AST, bil, calcium, CO2, creatinine, glucose and potassium. The number of participants with chemistry data of potential clinical importance for the mentioned parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 14
Number of Participants With Hematology Data of Clinical Importance
Blood samples were collected for the evaluation of hematology parameters including hematocrit, Hgb, lymphocytes, neutrophils and platelets. The number of participants with clinically significant abnormal values of the mentioned hematology parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 14
Change From Baseline in Immunoglobulin (Ig) A, IgG and IgM Levels
Blood samples were collected for the evaluation of change in IgA, IgG and IgM levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 12
Number of Participants With Ig Data Outside the Reference Range
Blood samples were collected for the evaluation of change in Ig levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 12
Number of Participants With Immunophenotyping Data Outside the Reference Range
Blood samples were collected for the evaluation of change in levels of cluster of differentiation (CD)19, CD3, CD3 Treg flow cytometry (CD3TFLC), CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T Cell B Cell Natural Killer Lymphocytes flow cytometry (T-B cell NKL). Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 12
Change From Baseline in Immunophenotype Data
Blood samples were collected for the evaluation of change from Baseline in immunophenotype levels including CD19, CD3, CD3TFLC, CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T-B cell NKL. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 12
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Pulse Rate
Pulse rate was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Change From Baseline in Temperature
Temperature was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Baseline and up to Week 14
Number of Participants With Vital Signs of Clinical Importance
The vital signs including SBP, DBP and pulse rate were measured from Baseline throughout the study. The number of participants with clinically significant abnormal vital signs were presented. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 14
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Single 12-lead ECGs were obtained over a brief recording period at each specified time point during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and corrected QT (QTc) intervals. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. For multiple ECGs at one visit, or "Any time post-screen", a participant is categorized as "Abnormal" if \>=1 assessment is abnormal. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
Time frame: Up to Week 14
This was a randomized, double-blind, dose-finding study of GSK2894512 in adult participants with psoriasis. The study consisted of 3 periods: 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of study for a participant was 16-20 weeks.
| Milestone | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Started | 38 | 38 | 38 | 38 | 37 | 38 |
| Completed | 27 | 30 | 32 | 35 | 26 | 24 |
| Not completed | 11 | 8 | 6 | 3 | 11 | 14 |
| Withdrew: Adverse event | 4 | 4 | 3 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 3 | 2 | 2 | 10 | 12 |
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. The analysis was performed on modified intent-to-treat (mITT) Population which comprised of all randomized participants except those enrolled at center ID 220008.
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Have a Physician Global Assessment (PGA) Score of 0 or 1 at Week 12 and a Minimum 2-grade Improvement in PGA Score From Baseline to Week 12 | 65 | 56 | 46 | 36 | 11 | 5 |
The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of body surface area (BSA) affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0 to 4) and the % BSA affected was scored on a 7-point scale (0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. Higher scores indicated more severe disease. The percentage of participants with \>=75% improvement in PASI from Baseline were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=32, 35, 31, 32, 28, 32 | 0 | 3 | 0 | 0 | 0 | 0 |
| Week 2, n=32, 33, 30, 32, 24, 30 | 6 | 15 | 3 | 3 | 0 | 0 |
| Week 4, n=28, 31, 29, 32, 22, 26 | 32 | 26 | 14 | 6 | 5 | 0 |
| Week 8, n=26, 27, 27, 32, 20, 20 | 50 | 37 | 37 | 34 | 5 | 0 |
| Week 12, n=23, 25, 26, 28, 19, 20 | 65 | 56 | 46 | 46 | 16 | 5 |
| Week 14, n=23, 26, 24, 27, 19, 19 | 65 | 65 | 46 | 48 | 16 | 5 |
| Week 16, n=24, 26, 26, 28, 19, 19 | 63 | 58 | 46 | 54 | 11 | 5 |
| Early withdrawal (EW), n=10, 7, 4, 2, 10, 9 | 10 | 43 | 0 | 0 | 0 | 0 |
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a minimum 2-grade improvement from Baseline for each study visit were summarized. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=32, 35, 31, 32, 28, 32 | 0 | 0 | 6 | 0 | 4 | 0 |
| Week 2, n=32, 33, 30, 32, 24, 30 | 13 | 12 | 13 | 6 | 0 | 0 |
| Week 4, n=28, 31, 29, 32, 22, 26 | 21 | 23 | 24 | 13 | 5 | 0 |
| Week 8, n=26, 27, 27, 32, 20, 20 | 46 | 37 | 41 | 41 | 0 | 0 |
| Week 12, n=23, 25, 26, 28, 19, 20 | 65 | 56 | 50 | 36 | 11 | 5 |
| Week 14, n=23, 26, 24, 27, 19, 19 | 61 | 62 | 38 | 37 | 5 | 0 |
| Week 16, n=24, 26, 26, 28, 19, 19 | 58 | 54 | 38 | 36 | 5 | 0 |
| EW, n=10, 7, 4, 2, 10, 9 | 20 | 43 | 25 | 0 | 0 | 0 |
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of participants who achieved a PGA score of 0 or 1 from Baseline at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=32, 35, 31, 32, 28, 32 | 0 | 9 | 3 | 0 | 4 | 0 |
| Week 2, n=32, 33, 30, 32, 24, 30 | 16 | 18 | 10 | 6 | 0 | 0 |
| Week 4, n=28, 31, 29, 32, 22, 26 | 21 | 42 | 24 | 16 | 5 | 4 |
| Week 8, n=26, 27, 27, 32, 20, 20 | 54 | 56 | 44 | 41 | 0 | 5 |
| Week 12, n=23, 25, 26, 28, 19, 20 | 70 | 72 | 54 | 39 | 11 | 10 |
| Week 14, n=23, 26, 24, 27, 19, 19 | 61 | 69 | 42 | 41 | 5 | 5 |
| Week 16, n=24, 26, 26, 28, 19, 19 | 58 | 65 | 50 | 43 | 5 | 5 |
| EW, n=10, 7, 4, 2, 10, 9 | 10 | 57 | 25 | 0 | 0 | 0 |
The extent of BSA affected by psoriasis is a general indicator of disease severity and was measured throughout the study. The extent of BSA to which study treatment was applied was also recorded. For the purpose of approximate clinical estimation, the total palmar surface of the palm plus 5 digits was assumed to be approximately equivalent to 1 percent BSA. Assessment of BSA affected with psoriasis was performed separately for four body surface regions: the head, the upper extremities, the trunk and the lower extremities, corresponding to 10, 20, 30 and 40 percent of the total body area, respectively. The mean change in percent BSA affected from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Percentage of BSA | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=32, 35, 31, 32, 28, 32 | -0.53 ± 1.136 | -0.30 ± 0.990 | -0.35 ± 0.774 | 0.02 ± 0.773 | -0.05 ± 0.510 | 0.01 ± 0.277 |
| Week 2, n=32, 33, 30, 32, 24, 30 | -1.06 ± 1.496 | -0.75 ± 1.789 | -0.79 ± 1.350 | -0.51 ± 1.157 | -0.18 ± 0.657 | -0.13 ± 1.159 |
| Week 4, n=28, 31, 29, 32, 22, 26 | -2.14 ± 3.275 | -2.13 ± 2.529 | -1.93 ± 2.951 | -0.80 ± 1.468 | -0.60 ± 1.332 | -0.17 ± 1.432 |
| Week 8, n=26, 27, 27, 32, 20, 20 | -3.37 ± 3.590 | -3.60 ± 3.220 | -3.51 ± 3.756 | -1.77 ± 2.800 | -1.05 ± 1.823 | -0.65 ± 1.435 |
| Week 12, n=23, 25, 26, 28, 19, 20 | -4.88 ± 4.211 | -4.28 ± 3.508 | -4.29 ± 3.882 | -3.59 ± 3.931 | -1.57 ± 2.380 | -0.98 ± 3.335 |
| Week 14, n=23, 26, 24, 27, 19, 19 | -5.01 ± 4.108 | -4.63 ± 3.548 | -4.26 ± 4.172 | -3.59 ± 4.201 | -1.33 ± 2.475 | -0.58 ± 3.634 |
| Week 16, n=24, 26, 26, 28, 19, 19 | -5.30 ± 4.468 | -4.47 ± 3.833 | -4.34 ± 4.299 | -3.56 ± 4.716 | -1.18 ± 2.490 | -1.10 ± 3.627 |
| EW, n=10, 7, 4, 2, 10, 9 | -1.92 ± 2.218 | -2.31 ± 3.465 | 0.25 ± 1.893 | 1.25 ± 9.546 | 0.74 ± 1.536 | 1.17 ± 2.094 |
The PASI is a standard clinical tool for assessing the severity of psoriasis based on severity of erythema, thickness and scale, as well as the extent of BSA affected with psoriasis. The 3 clinical signs were graded on a 5 point scale (0=None to 4=Severe) and the percent of BSA affected is scored on a 7-point scale (0=0% involvement to 6=90-100%) for each of 4 specified body regions (head, upper extremities, trunk and lower extremities). The individual scores were multiplied by a weighted factor for each body region. The sum of these scores gave the overall PASI score. PASI score ranged from 0=no psoriasis to 72=worse psoriasis. The mean change in PASI score from Baseline was summarized for each study visit. Baseline was the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=32, 35, 31, 32, 28, 32 | -2.22 ± 2.795 | -1.73 ± 2.374 | -1.11 ± 2.083 | -1.33 ± 1.807 | -0.85 ± 1.203 | -0.28 ± 1.165 |
| Week 2, n=32, 33, 30, 32, 24, 30 | -4.10 ± 3.756 | -3.07 ± 3.016 | -2.39 ± 3.118 | -2.49 ± 2.316 | -1.78 ± 2.826 | -0.61 ± 1.644 |
| Week 4, n=28, 31, 29, 32, 22, 26 | -6.07 ± 5.051 | -4.45 ± 3.072 | -3.83 ± 3.827 | -3.31 ± 2.796 | -2.88 ± 3.308 | -1.08 ± 2.026 |
| Week 8, n=26, 27, 27, 32, 20, 20 | -7.52 ± 5.612 | -5.77 ± 3.556 | -5.79 ± 5.055 | -4.58 ± 3.902 | -2.82 ± 4.081 | -1.34 ± 2.288 |
| Week 12, n=23, 25, 26, 28, 19, 20 | -8.70 ± 5.617 | -6.62 ± 3.709 | -6.30 ± 5.138 | -5.41 ± 4.424 | -2.77 ± 4.291 | -1.54 ± 2.970 |
| Week 14, n=23, 26, 24, 27, 19, 19 | -8.61 ± 5.328 | -6.65 ± 3.973 | -5.67 ± 5.100 | -5.28 ± 4.422 | -2.60 ± 4.491 | -1.29 ± 3.280 |
| Week 16, n=24, 26, 26, 28, 19, 19 | -8.46 ± 5.432 | -6.63 ± 4.067 | -5.65 ± 5.646 | -5.13 ± 4.712 | -2.41 ± 4.285 | -1.09 ± 3.914 |
| EW, n=10, 7, 4, 2, 10, 9 | -3.70 ± 3.391 | -4.00 ± 3.636 | -1.18 ± 1.167 | 1.50 ± 8.627 | -0.06 ± 2.784 | 0.12 ± 2.742 |
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean of PGA scores at each study visit was summarized. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Baseline, n=34, 35, 32, 32, 30, 33 | 2.9 ± 0.42 | 2.7 ± 0.51 | 3.0 ± 0.54 | 2.9 ± 0.39 | 3.0 ± 0.26 | 2.8 ± 0.44 |
| Week 1, n=32, 35, 31, 32, 28, 32 | 2.7 ± 0.59 | 2.4 ± 0.65 | 2.7 ± 0.65 | 2.6 ± 0.56 | 2.9 ± 0.52 | 2.8 ± 0.51 |
| Week 2, n=32, 33, 30, 32, 24, 30 | 2.3 ± 0.77 | 2.2 ± 0.71 | 2.4 ± 0.67 | 2.5 ± 0.62 | 2.6 ± 0.50 | 2.6 ± 0.49 |
| Week 4, n=28, 31, 29, 32, 22, 26 | 2.0 ± 0.67 | 1.6 ± 0.71 | 2.1 ± 0.77 | 2.1 ± 0.78 | 2.4 ± 0.59 | 2.6 ± 0.64 |
| Week 8, n=26, 27, 27, 32, 20, 20 | 1.5 ± 0.86 | 1.4 ± 0.80 | 1.6 ± 0.75 | 1.7 ± 0.85 | 2.5 ± 0.51 | 2.5 ± 0.61 |
| Week 12, n=23, 25, 26, 28, 19, 20 | 1.1 ± 0.92 | 1.1 ± 0.81 | 1.3 ± 1.01 | 1.6 ± 0.78 | 2.4 ± 0.69 | 2.5 ± 0.69 |
| Week 14, n=23, 26, 24, 27, 19, 19 | 1.3 ± 1.01 | 1.1 ± 0.99 | 1.6 ± 0.88 | 1.7 ± 0.94 | 2.5 ± 0.61 | 2.5 ± 0.61 |
| Week 16, n=24, 26, 26, 28, 19, 19 | 1.3 ± 1.08 | 1.2 ± 1.01 | 1.5 ± 0.90 | 1.7 ± 1.06 | 2.5 ± 0.61 | 2.6 ± 0.69 |
| EW, n=10, 7, 4, 2, 10, 9 | 2.5 ± 1.08 | 1.6 ± 1.40 | 2.0 ± 1.41 | 2.5 ± 0.71 | 3.1 ± 0.57 | 3.1 ± 0.60 |
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The mean change in PGA scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=32, 35, 31, 32, 28, 32 | -0.3 ± 0.44 | -0.3 ± 0.48 | -0.3 ± 0.69 | -0.3 ± 0.47 | -0.1 ± 0.52 | -0.1 ± 0.30 |
| Week 2, n=32, 33, 30, 32, 24, 30 | -0.7 ± 0.75 | -0.6 ± 0.70 | -0.6 ± 0.77 | -0.4 ± 0.62 | -0.4 ± 0.49 | -0.2 ± 0.50 |
| Week 4, n=28, 31, 29, 32, 22, 26 | -1.0 ± 0.69 | -1.1 ± 0.70 | -0.9 ± 0.83 | -0.8 ± 0.78 | -0.5 ± 0.60 | -0.2 ± 0.51 |
| Week 8, n=26, 27, 27, 32, 20, 20 | -1.4 ± 0.90 | -1.3 ± 0.88 | -1.4 ± 0.84 | -1.2 ± 0.97 | -0.5 ± 0.60 | -0.4 ± 0.49 |
| Week 12, n=23, 25, 26, 28, 19, 20 | -1.8 ± 0.90 | -1.7 ± 1.03 | -1.7 ± 1.06 | -1.3 ± 0.81 | -0.5 ± 0.77 | -0.4 ± 0.67 |
| Week 14, n=23, 26, 24, 27, 19, 19 | -1.7 ± 0.93 | -1.6 ± 1.20 | -1.4 ± 0.88 | -1.2 ± 0.92 | -0.5 ± 0.70 | -0.4 ± 0.50 |
| Week 16, n=24, 26, 26, 28, 19, 19 | -1.6 ± 1.01 | -1.6 ± 1.24 | -1.4 ± 0.90 | -1.3 ± 1.00 | -0.4 ± 0.69 | -0.3 ± 0.56 |
| EW, n=10, 7, 4, 2, 10, 9 | -0.5 ± 1.18 | -1.3 ± 1.38 | -1.0 ± 1.41 | 0.0 ± 1.41 | 0.0 ± 0.47 | 0.1 ± 0.60 |
A single target lesion of at least 3 centimeter (cm) x 3 cm was selected at Baseline. For the selected lesion, the severity of erythema, scaling and plaque thickness (induration) was assessed by the investigator on a 5-point scale ranging from 0=none to 4=severe. The mean change in individual grading scores from Baseline was summarized for each study visit. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Scaling; Week 1, n=32, 35, 31, 32, 28, 32 | -0.7 ± 0.70 | -0.7 ± 0.90 | -0.4 ± 0.76 | -0.6 ± 0.56 | -0.5 ± 0.69 | -0.3 ± 0.44 |
| Scaling; Week 2, n=32, 33, 30, 32, 24, 30 | -0.9 ± 0.78 | -1.0 ± 1.07 | -0.9 ± 0.87 | -1.0 ± 0.84 | -1.0 ± 0.75 | -0.3 ± 0.80 |
| Scaling; Week 4, n=28, 31, 29, 32, 22, 26 | -1.5 ± 0.88 | -1.5 ± 1.21 | -1.4 ± 0.95 | -1.4 ± 0.98 | -1.0 ± 0.84 | -0.4 ± 0.80 |
| Scaling; Week 8, n=26, 27, 27, 32, 20, 20 | -2.0 ± 1.11 | -2.0 ± 1.19 | -1.7 ± 1.07 | -1.9 ± 1.03 | -1.2 ± 0.93 | -0.4 ± 0.81 |
| Scaling; Week 12, n=23, 25, 26, 29, 19, 20 | -2.3 ± 0.96 | -2.4 ± 1.15 | -2.1 ± 1.07 | -2.0 ± 1.05 | -1.0 ± 1.11 | -0.7 ± 0.81 |
| Scaling; Week 14, n=23, 26, 24, 27, 19, 19 | -2.1 ± 1.20 | -2.2 ± 1.43 | -1.7 ± 1.17 | -1.8 ± 1.37 | -0.7 ± 1.05 | -0.5 ± 0.77 |
| Scaling; Week 16, n=24, 26, 26, 28, 19, 19 | -2.1 ± 1.19 | -2.2 ± 1.24 | -1.6 ± 1.45 | -1.8 ± 1.29 | -0.6 ± 1.07 | -0.3 ± 0.67 |
| Scaling; EW, n=10, 7, 4, 2, 10, 9 | -1.5 ± 1.27 | -1.6 ± 1.27 | -1.3 ± 1.50 | -0.5 ± 0.71 | -0.5 ± 0.97 | 0.0 ± 0.71 |
| Erythema; Week 1, n=32, 35, 31, 32, 28, 32 | -0.4 ± 0.66 | -0.5 ± 0.78 | -0.3 ± 0.64 | -0.4 ± 0.50 | -0.2 ± 0.48 | -0.1 ± 0.39 |
| Erythema; Week 2, n=32, 33, 30, 32, 24, 30 | -0.8 ± 0.83 | -1.1 ± 0.97 | -0.7 ± 0.94 | -0.8 ± 0.74 | -0.3 ± 0.75 | -0.2 ± 0.48 |
| Erythema; Week 4, n=28, 31, 29, 32, 22, 26 | -1.3 ± 0.90 | -1.5 ± 0.89 | -1.3 ± 0.85 | -1.1 ± 0.80 | -0.6 ± 0.85 | -0.4 ± 0.64 |
| Erythema; Week 8, n=26, 27, 27, 32, 20, 20 | -1.8 ± 1.10 | -2.0 ± 1.04 | -1.9 ± 0.95 | -1.5 ± 0.92 | -0.8 ± 0.85 | -0.5 ± 0.76 |
| Erythema; Week 12, n=23, 25, 26, 29, 19, 20 | -2.3 ± 1.10 | -2.5 ± 1.08 | -2.2 ± 1.01 | -1.9 ± 1.13 | -0.5 ± 1.07 | -0.8 ± 0.97 |
| Erythema; Week 14, n=23, 26, 24, 27, 19, 19 | -2.1 ± 1.28 | -2.2 ± 1.21 | -1.9 ± 0.95 | -1.7 ± 1.27 | -0.6 ± 1.12 | -0.9 ± 0.91 |
| Erythema; Week 16, n=24, 26, 26, 28, 19, 19 | -2.1 ± 1.23 | -2.3 ± 1.09 | -1.8 ± 1.10 | -2.0 ± 1.26 | -0.6 ± 0.96 | -0.5 ± 0.90 |
| Erythema; EW, n=10, 7, 4, 2, 10, 9 | -1.3 ± 1.06 | -1.4 ± 1.40 | -0.8 ± 1.50 | 0.0 ± 1.41 | -0.5 ± 0.97 | -0.1 ± 0.60 |
| Plaque thickness; Week 1, n=32,35,31,32,28,32 | -0.5 ± 0.67 | -0.5 ± 0.82 | -0.4 ± 0.56 | -0.3 ± 0.60 | -0.4 ± 0.50 | -0.2 ± 0.45 |
| Plaque thickness; Week 2, n=32,33,30,32,24,30 | -0.9 ± 0.84 | -0.9 ± 1.01 | -0.9 ± 0.94 | -0.8 ± 0.80 | -0.7 ± 0.76 | -0.3 ± 0.66 |
| Plaque thickness; Week 4, n=28,31,29,32,22,26 | -1.4 ± 1.03 | -1.5 ± 1.26 | -1.3 ± 1.00 | -1.2 ± 0.93 | -1.0 ± 0.65 | -0.4 ± 0.64 |
| Plaque thickness; Week 8, n=26,27,27,32,20,20 | -1.8 ± 1.17 | -1.8 ± 1.15 | -1.8 ± 1.09 | -1.7 ± 1.12 | -0.9 ± 0.88 | -0.5 ± 0.60 |
| Plaque thickness; Week 12, n=23,25,26,29,19,20 | -2.3 ± 0.93 | -2.1 ± 1.19 | -1.9 ± 1.20 | -1.9 ± 1.13 | -1.0 ± 0.94 | -0.7 ± 0.80 |
| Plaque thickness; Week 14, n=23,26,24,27,19,19 | -2.1 ± 1.16 | -2.1 ± 1.20 | -1.8 ± 1.19 | -1.7 ± 1.32 | -0.9 ± 1.13 | -0.7 ± 0.87 |
| Plaque thickness; Week 16, n=24,26 26,28,19,19 | -2.1 ± 1.19 | -2.1 ± 1.32 | -1.6 ± 1.39 | -1.8 ± 1.31 | -0.7 ± 1.10 | -0.4 ± 0.69 |
| Plaque thickness; EW, n=10,7,4,2,10,9 | -1.3 ± 1.06 | -1.9 ± 1.21 | -1.0 ± 1.41 | 0.0 ± 0.00 | -0.6 ± 1.07 | 0.4 ± 0.73 |
The participant reported itch severity was obtained from the response of the participants to the itch NRS item in the psoriasis symptom diary (PSD). PSD was developed to assess daily self-reports of psoriasis symptoms and the functional impact related to the underlying pathophysiology of the disease. The participants answered questions related to the severity and impact of the signs and symptoms daily using a 11 point NRS with scores ranging from 0 (absent) to 10 (worst imaginable). Mean change in itch/pruritis NRS from Baseline to each study visit was presented. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the post dose weekly average value minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Scores on a scale | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=28, 33, 21, 31, 21, 29 | -0.66 ± 1.800 | -0.17 ± 2.007 | -1.00 ± 2.038 | -0.32 ± 1.710 | -1.31 ± 1.689 | -0.63 ± 1.612 |
| Week 2, n=27, 30, 22, 32, 20, 25 | -1.62 ± 2.334 | -0.85 ± 1.870 | -1.97 ± 2.366 | -1.24 ± 1.949 | -1.66 ± 2.444 | -1.12 ± 2.147 |
| Week 4, n=20, 25, 21, 30, 17, 24 | -2.35 ± 3.057 | -1.78 ± 2.402 | -3.13 ± 2.075 | -1.91 ± 2.723 | -1.67 ± 2.727 | -1.31 ± 2.338 |
| Week 8, n=18, 22, 20, 29, 16, 20 | -3.66 ± 3.248 | -1.93 ± 2.543 | -3.29 ± 2.605 | -2.06 ± 2.842 | -1.98 ± 3.239 | -1.43 ± 2.664 |
| Week 12, n=14, 20, 21, 24, 15, 18 | -3.53 ± 2.933 | -2.59 ± 2.923 | -3.65 ± 2.605 | -2.73 ± 2.922 | -2.46 ± 3.389 | -1.43 ± 2.765 |
| Week 14, n=13, 14, 15, 24, 15, 13 | -3.56 ± 2.698 | -3.52 ± 2.489 | -3.58 ± 2.296 | -2.24 ± 3.067 | -1.90 ± 2.643 | -2.19 ± 2.898 |
| Week 16, n=10, 9, 12, 19, 13, 10 | -3.67 ± 3.766 | -2.19 ± 2.695 | -3.66 ± 2.059 | -2.25 ± 2.992 | -2.36 ± 2.837 | -2.06 ± 3.225 |
| EW, n=6, 3, 2, 0, 5, 5 | -1.77 ± 1.647 | -0.07 ± 1.501 | -5.67 ± 6.128 | — | -1.79 ± 1.654 | -0.51 ± 1.391 |
The PGA is a clinical tool for assessing the current state/severity of a participant's psoriasis. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, plaque thickness, and scaling as guidelines. Each assessment was made as a visual 'average' of the severity of all treated areas at the time of the assessment. The scores ranged from 0 to 4 where 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate and 4=Severe. The percentage of responders that is, participants who achieved a PGA score of 0 or 1 and a minimum 2-grade improvement from baseline were summarized. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Percentage of participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=32, 35, 31, 32, 28, 32 | 0 | 0 | 3 | 0 | 4 | 0 |
| Week 2, n=32, 33, 30, 32, 24, 30 | 9 | 9 | 10 | 6 | 0 | 0 |
| Week 4, n=28, 31, 29, 32, 22, 26 | 14 | 19 | 17 | 13 | 5 | 0 |
| Week 8, n=26, 27, 27, 32, 20, 20 | 42 | 37 | 33 | 41 | 0 | 0 |
| Week 12, n=23, 25, 26, 28, 19, 20 | 65 | 56 | 46 | 36 | 11 | 5 |
| Week 14, n=23, 26, 24, 27, 19, 19 | 57 | 62 | 29 | 37 | 5 | 0 |
| Week 16, n=24, 26, 26, 28, 19, 19 | 58 | 54 | 35 | 36 | 5 | 0 |
| EW, n=10, 7, 4, 2, 10, 9 | 10 | 43 | 25 | 0 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. A TEAE is defined as an AE which occurred on or after study treatment start date and on or before the last visit. Number of participants with AEs and SAEs were presented. The analysis was performed on safety Population which comprised of all participants who received at least one dose of study treatment.
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| TEAEs | 26 | 20 | 22 | 17 | 9 | 10 |
| serious TEAEs | 1 | 3 | 3 | 0 | 0 | 0 |
The assessment of the presence and degree of burning/stinging and itching at the application site following application of the study treatment was done at each specified study visit using a 5 point tolerability scale. The scores ranged from 0 to 4 where 0=None and 4=Strong/Severe. The score represented an average across all application sites. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, none, n=36, 38, 37,38, 35, 37 | 19 | 17 | 18 | 26 | 19 | 26 |
| Week 1, slight, n=36, 38, 37,38, 35, 37 | 4 | 8 | 7 | 1 | 6 | 8 |
| Week 1, mild, n=36, 38, 37,38, 35, 37 | 8 | 9 | 5 | 8 | 6 | 2 |
| Week 1, moderate, n=36, 38, 37,38, 35, 37 | 4 | 4 | 6 | 3 | 2 | 1 |
| Week 1, strong/severe, n=36, 38, 37,38, 35, 37 | 1 | 0 | 1 | 0 | 2 | 0 |
| Week 2, none, n=36, 36, 36,38, 31, 35 | 24 | 28 | 20 | 31 | 23 | 26 |
| Week 2, slight, n=36, 36, 36,38, 31, 35 | 4 | 4 | 7 | 4 | 4 | 5 |
| Week 2, mild, n=36, 36, 36,38, 31, 35 | 7 | 4 | 3 | 2 | 1 | 4 |
| Week 2, moderate, n=36, 36, 36,38, 31, 35 | 1 | 0 | 6 | 1 | 1 | 0 |
| Week 2, strong/severe, n=36, 36, 36,38, 31, 35 | 0 | 0 | 0 | 0 | 2 | 0 |
| Week 4, none, n=32, 34, 35,38, 29, 31 | 19 | 24 | 23 | 32 | 21 | 26 |
| Week 4, slight, n=32, 34, 35,38, 29, 31 | 7 | 5 | 4 | 2 | 3 | 3 |
| Week 4, mild, n=32, 34, 35,38, 29, 31 | 4 | 4 | 5 | 3 | 3 | 1 |
| Week 4, moderate, n=32, 34, 35,38, 29, 31 | 2 | 1 | 3 | 1 | 1 | 1 |
| Week 4, strong/severe, n=32, 34, 35,38, 29, 31 | 0 | 0 | 0 | 0 | 1 | 0 |
| Week 8, none, n=30, 31, 33,38, 27, 26 | 24 | 24 | 24 | 33 | 24 | 22 |
| Week 8, slight, n=30, 31, 33,38, 27, 26 | 4 | 7 | 5 | 3 | 3 | 2 |
| Week 8, mild, n=30, 31, 33,38, 27, 26 | 1 | 0 | 3 | 1 | 0 | 0 |
| Week 8, moderate, n=30, 31, 33,38, 27, 26 | 1 | 0 | 1 | 1 | 0 | 2 |
| Week 8, strong/severe, n=30, 31, 33,38, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 12, none, n=27, 29, 32,35, 26, 25 | 20 | 24 | 25 | 31 | 24 | 23 |
| Week 12, slight, n=27, 29, 32,35, 26, 25 | 4 | 2 | 3 | 3 | 2 | 1 |
| Week 12, mild, n=27, 29, 32,35, 26, 25 | 2 | 3 | 3 | 1 | 0 | 0 |
| Week 12, moderate, n=27, 29, 32,35, 26, 25 | 1 | 0 | 1 | 0 | 0 | 1 |
| Week 12, strong/severe, n=27, 29, 32,35, 26, 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 14, none, n=27, 30, 33, 33, 27, 24 | 24 | 25 | 25 | 31 | 25 | 23 |
| Week 14, slight, n=27, 30, 33, 33, 27, 24 | 1 | 3 | 3 | 2 | 1 | 0 |
| Week 14, mild, n=27, 30, 33, 33, 27, 24 | 1 | 1 | 3 | 0 | 1 | 0 |
| Week 14, moderate, n=27, 30, 33, 33, 27, 24 | 1 | 1 | 2 | 0 | 0 | 1 |
| Week 14, strong/severe, n=27, 30, 33, 33, 27, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| EW, none, n=9, 7, 4, 2, 10, 9 | 4 | 2 | 0 | 2 | 4 | 8 |
| EW, slight, n=9, 7, 4, 2, 10, 9 | 1 | 2 | 1 | 0 | 2 | 0 |
| EW, mild, n=9, 7, 4, 2, 10, 9 | 0 | 0 | 2 | 0 | 2 | 0 |
| EW, moderate, n=9, 7, 4, 2, 10, 9 | 2 | 1 | 0 | 0 | 1 | 1 |
| EW, strong/severe, n=9,7,4, 2, 10, 9 | 2 | 2 | 1 | 0 | 1 | 0 |
Blood samples were collected for the evaluation of change in albumin and protein levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| grams/liter (g/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Albumin, Week 2, n=35, 36, 35, 37, 29, 34 | -0.9 ± 2.11 | -1.1 ± 2.70 | -0.9 ± 2.83 | -1.1 ± 2.33 | -0.9 ± 3.37 | -0.6 ± 2.76 |
| Albumin, Week 4, n=32, 34, 33, 37, 29, 30 | -1.3 ± 2.10 | -1.2 ± 2.52 | -1.0 ± 3.57 | -0.4 ± 1.99 | -0.8 ± 3.53 | -0.2 ± 3.23 |
| Albumin, Week 8, n=30, 31, 32, 37, 27, 26 | -1.0 ± 1.65 | -0.6 ± 2.33 | -1.0 ± 3.33 | -1.0 ± 2.49 | -0.6 ± 3.19 | -1.0 ± 2.36 |
| Albumin, Week 12, n=27, 30, 32, 36, 26, 24 | -0.8 ± 2.19 | -0.5 ± 3.31 | -1.3 ± 3.39 | -1.2 ± 1.67 | -0.6 ± 3.14 | -1.1 ± 2.85 |
| Albumin, Week 14, n=29, 31, 33, 34, 27, 24 | -1.3 ± 2.74 | -1.1 ± 2.72 | -1.5 ± 2.71 | -1.1 ± 2.81 | -1.6 ± 4.24 | -2.0 ± 2.40 |
| Albumin, EW, n=10, 6, 3, 2, 10, 9 | -0.3 ± 2.06 | -1.7 ± 2.50 | 0.0 ± 3.46 | -3.5 ± 3.54 | -0.8 ± 1.99 | -0.2 ± 2.54 |
| Protein, Week 2, n=35, 36, 35, 37, 29, 34 | -1.1 ± 3.84 | -2.5 ± 3.95 | -1.3 ± 4.25 | -1.5 ± 3.07 | -1.8 ± 4.21 | -1.0 ± 4.25 |
| Protein, Week 4, n=32, 34, 33, 37, 29, 30 | -2.3 ± 3.23 | -2.9 ± 3.41 | -0.9 ± 4.94 | -0.7 ± 3.37 | -1.9 ± 4.99 | -0.3 ± 4.70 |
| Protein, Week 8, n=30, 31, 32, 37, 27, 26 | -2.1 ± 3.28 | -1.7 ± 3.74 | -1.9 ± 4.88 | -1.3 ± 3.89 | -1.5 ± 4.42 | -1.4 ± 3.30 |
| Protein, Week 12, n=27, 30, 32, 36, 26, 24 | -1.3 ± 2.73 | -2.5 ± 3.72 | -2.4 ± 4.23 | -1.7 ± 3.27 | -1.8 ± 4.05 | -1.5 ± 3.84 |
| Protein, Week 14, n=29, 31, 33, 34, 27, 24 | -2.1 ± 3.06 | -2.9 ± 3.61 | -2.4 ± 4.34 | -1.9 ± 4.01 | -3.0 ± 4.32 | -2.6 ± 2.81 |
| Protein, EW, n=10, 6, 3, 2, 10, 9 | -0.8 ± 2.66 | -3.5 ± 3.83 | -3.0 ± 5.00 | -3.5 ± 2.12 | -1.2 ± 3.52 | -0.2 ± 3.42 |
Blood samples were collected for the evaluation of change in levels of alk phos, ALT, AST and GGT from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| International Units (IU)/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Alk. Phos, Week 2, n=35, 36, 35, 37, 29, 34 | -0.6 ± 10.83 | -0.9 ± 8.44 | -0.7 ± 13.47 | -2.9 ± 10.93 | 0.7 ± 18.06 | -2.1 ± 7.02 |
| Alk. Phos, Week 4, n=32, 34, 33, 37, 29, 30 | -0.2 ± 20.50 | -0.6 ± 7.03 | 0.1 ± 13.51 | 0.4 ± 11.33 | -0.0 ± 14.42 | -2.9 ± 8.69 |
| Alk. Phos, Week 8, n=30, 31, 32, 37, 27, 26 | -4.1 ± 17.59 | -1.2 ± 11.06 | -0.1 ± 9.53 | -3.9 ± 9.54 | 0.0 ± 12.56 | 2.3 ± 11.25 |
| Alk. Phos, Week 12, n=27, 30, 32, 36, 26, 24 | -5.7 ± 18.74 | -3.1 ± 10.45 | -1.7 ± 9.29 | -2.3 ± 8.30 | -1.7 ± 15.72 | 1.2 ± 13.29 |
| Alk. Phos, Week 14, n=29, 31, 33, 34, 27, 24 | -2.3 ± 15.62 | -4.1 ± 10.56 | -3.1 ± 12.34 | -4.9 ± 13.20 | -2.4 ± 16.98 | -2.8 ± 13.62 |
| Alk. Phos, EW, n=10, 6, 3, 2, 10, 9 | -3.7 ± 7.27 | 2.7 ± 10.95 | 7.7 ± 16.80 | -13.5 ± 6.36 | -3.4 ± 10.51 | -1.8 ± 9.13 |
| ALT, Week 2, n=35, 36, 35, 37, 29, 34 | -2.1 ± 7.98 | -2.6 ± 7.95 | -2.3 ± 6.18 | -2.9 ± 9.75 | -2.7 ± 13.45 | -1.3 ± 4.54 |
| ALT, Week 4, n=32, 34, 33, 37, 29, 30 | 0.3 ± 22.68 | -2.7 ± 5.99 | -3.7 ± 13.21 | -2.9 ± 9.91 | -2.4 ± 11.83 | 2.3 ± 9.10 |
| ALT, Week 8, n=30, 31, 32, 37, 27, 26 | -1.5 ± 10.37 | -3.9 ± 12.47 | 0.1 ± 11.68 | -4.4 ± 10.88 | 0.3 ± 14.28 | -0.4 ± 10.21 |
| ALT, Week 12, n=27, 30, 32, 36, 26, 24 | -1.8 ± 15.35 | -2.2 ± 8.25 | -0.1 ± 13.72 | -5.4 ± 9.54 | -2.6 ± 14.93 | 1.5 ± 20.39 |
| ALT, Week 14, n=29, 31, 33, 34, 27, 24 | -3.8 ± 17.42 | -3.5 ± 10.37 | -1.8 ± 12.99 | -6.5 ± 10.33 | -1.4 ± 19.63 | -1.7 ± 9.27 |
| ALT, EW, n=10, 6, 3, 2, 10, 9 | -1.1 ± 5.02 | -2.2 ± 7.31 | 5.0 ± 16.64 | -5.0 ± 7.07 | -8.2 ± 12.16 | -1.3 ± 5.52 |
| AST, Week 2, n=35, 36, 35, 37, 29, 34 | -0.6 ± 4.91 | -1.2 ± 5.09 | 0.5 ± 3.71 | -1.8 ± 11.91 | -2.3 ± 10.76 | -1.0 ± 5.70 |
| AST, Week 4, n=32, 34, 33, 37, 29, 30 | 0.2 ± 9.76 | -1.9 ± 3.21 | -1.0 ± 5.22 | -3.1 ± 11.61 | -1.9 ± 9.05 | 0.5 ± 6.66 |
| AST, Week 8, n=30, 31, 32, 37, 27, 26 | -1.0 ± 4.22 | -2.2 ± 6.32 | 2.6 ± 11.60 | -4.2 ± 11.50 | -0.3 ± 10.52 | -1.7 ± 8.47 |
| AST, Week 12, n=27, 30, 32, 36, 26, 24 | 0.6 ± 9.09 | -2.2 ± 7.49 | 1.9 ± 8.89 | -4.1 ± 9.90 | -1.6 ± 12.75 | -0.3 ± 8.45 |
| AST, Week 14, n=29, 31, 33, 34, 27, 24 | -0.4 ± 7.55 | -2.7 ± 8.76 | 0.7 ± 8.39 | -5.1 ± 11.36 | -1.3 ± 13.40 | -1.0 ± 6.92 |
| AST, EW, n=10, 6, 3, 2, 10, 9 | -1.0 ± 4.24 | 5.2 ± 15.84 | 1.7 ± 9.07 | -1.0 ± 4.24 | -3.7 ± 7.73 | -0.3 ± 7.48 |
| GGT, Week 2, n=35, 36, 35, 37, 29, 34 | -1.0 ± 6.63 | -2.1 ± 8.38 | -0.4 ± 17.64 | -1.6 ± 14.39 | -3.1 ± 15.17 | -4.5 ± 9.92 |
| GGT, Week 4, n=32, 34, 33, 37, 29, 30 | 8.5 ± 56.71 | -3.5 ± 17.84 | -4.6 ± 22.06 | 0.3 ± 15.40 | -2.5 ± 18.08 | -2.1 ± 11.77 |
| GGT, Week 8, n=30, 31, 32, 37, 27, 26 | 1.9 ± 20.56 | -7.6 ± 32.91 | -1.2 ± 21.11 | -3.2 ± 20.11 | -3.1 ± 23.93 | -0.4 ± 13.61 |
| GGT, Week 12, n=27, 30, 32, 36, 26, 24 | -0.1 ± 24.48 | -2.4 ± 12.78 | 2.1 ± 20.03 | -5.9 ± 12.56 | -3.7 ± 30.64 | 3.3 ± 23.10 |
| GGT, Week 14, n=29, 31, 33, 34, 27, 24 | -1.9 ± 16.31 | -2.5 ± 11.69 | -0.1 ± 16.58 | -5.9 ± 17.67 | -0.5 ± 38.93 | -1.3 ± 11.15 |
| GGT, EW, n=10, 6, 3, 2, 10, 9 | -2.0 ± 6.25 | -5.3 ± 7.42 | -2.0 ± 6.56 | -2.5 ± 7.78 | -2.6 ± 4.65 | -10.1 ± 25.73 |
Blood samples were collected for the evaluation of change in levels of direct bil, bil, creatinine and urate from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| micromoles (µmol)/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Direct bil, Week 2, n=35, 36, 35, 37, 29, 34 | -0.2 ± 0.81 | -0.4 ± 1.36 | 0.0 ± 1.08 | -0.1 ± 1.24 | -0.1 ± 1.51 | 0.0 ± 0.85 |
| Direct bil, Week 4, n=32, 34, 33, 37, 29, 30 | -0.3 ± 0.67 | -0.5 ± 1.50 | -0.1 ± 1.17 | -0.2 ± 0.99 | -0.1 ± 1.36 | -0.1 ± 1.17 |
| Direct bil, Week 8, n=30, 31, 32, 37, 27, 26 | -0.4 ± 0.97 | -0.3 ± 1.24 | -0.2 ± 0.93 | -0.2 ± 1.03 | -0.1 ± 1.35 | -0.5 ± 1.33 |
| Direct bil, Week 12, n=27, 30, 32, 36, 26, 24 | -0.2 ± 0.64 | -0.3 ± 1.26 | -0.2 ± 1.18 | -0.4 ± 1.15 | 0.0 ± 1.26 | -0.1 ± 1.10 |
| Direct bil, Week 14, n=29, 31, 33, 34, 27, 24 | 0.1 ± 1.19 | -0.3 ± 1.28 | -0.1 ± 1.06 | -0.1 ± 1.04 | 0.1 ± 1.52 | -0.2 ± 0.82 |
| Direct bil, EW, n=10, 6, 3, 2, 10, 9 | 0.2 ± 1.14 | 0.0 ± 0.00 | 0.0 ± 0.00 | 2.0 ± 0.00 | -0.4 ± 1.26 | -0.2 ± 1.20 |
| Bil, Week 2, n=35, 36, 35, 37, 29, 34 | -0.7 ± 3.03 | -1.4 ± 3.24 | -0.6 ± 2.98 | -0.3 ± 2.56 | -0.3 ± 4.40 | 0.8 ± 4.15 |
| Bil, Week 4, n=32, 34, 33, 37, 29, 30 | -0.4 ± 3.50 | -1.2 ± 3.42 | 0.4 ± 4.34 | -0.6 ± 2.87 | -0.6 ± 4.84 | 1.7 ± 4.29 |
| Bil, Week 8, n=30, 31, 32, 37, 27, 26 | -0.3 ± 2.86 | 0.1 ± 2.73 | -0.8 ± 2.48 | -0.3 ± 3.06 | -0.9 ± 4.27 | 0.2 ± 3.81 |
| Bil, Week 12, n=27, 30, 32, 36, 26, 24 | -0.2 ± 2.10 | -0.7 ± 2.70 | -0.9 ± 3.13 | -0.4 ± 3.13 | -0.4 ± 4.93 | 0.6 ± 4.02 |
| Bil, Week 14, n=29, 31, 33, 34, 27, 24 | 0.6 ± 3.70 | -0.7 ± 4.34 | -0.9 ± 2.74 | -0.5 ± 3.56 | -0.8 ± 4.84 | 0.5 ± 2.96 |
| Bil, EW, n=10, 6, 3, 2, 10, 9 | -0.8 ± 2.53 | 0.0 ± 2.19 | 2.7 ± 3.06 | -1.0 ± 1.41 | 0.4 ± 3.10 | -0.2 ± 3.23 |
| Creatinine, Week 2, n=35, 36, 35, 37, 29, 34 | -0.26 ± 7.565 | 0.86 ± 9.588 | 1.14 ± 7.202 | 0.27 ± 9.708 | -1.65 ± 5.812 | 1.22 ± 6.632 |
| Creatinine, Week 4, n=32, 34, 33, 37, 29, 30 | -2.27 ± 6.493 | 0.12 ± 8.469 | 0.97 ± 7.802 | 1.81 ± 7.510 | -2.38 ± 6.095 | 1.57 ± 10.282 |
| Creatinine, Week 8, n=30, 31, 32, 37, 27, 26 | -0.09 ± 6.792 | 0.55 ± 7.030 | 0.48 ± 7.086 | 2.82 ± 11.713 | -2.89 ± 7.566 | 1.40 ± 8.515 |
| Creatinine, Week 12, n=27, 30, 32, 36, 26, 24 | 2.39 ± 7.526 | 0.14 ± 6.543 | 0.34 ± 6.852 | 0.37 ± 11.501 | -4.35 ± 10.528 | 1.49 ± 7.718 |
| Creatinine, Week 14, n=29, 31, 33, 34, 27, 24 | 1.74 ± 5.748 | 1.67 ± 7.316 | 3.41 ± 7.309 | 1.67 ± 14.096 | -2.33 ± 9.715 | 3.06 ± 8.970 |
| Creatinine, EW, n=10, 6, 3, 2, 10, 9 | -0.80 ± 8.570 | -5.02 ± 9.374 | 21.77 ± 31.832 | -1.80 ± 0.000 | -1.58 ± 6.009 | -2.36 ± 5.544 |
| Urate, Week 2, n=35, 36, 35, 37, 29, 34 | -6.0 ± 55.26 | -7.8 ± 40.29 | 15.4 ± 41.96 | 6.2 ± 61.07 | -8.3 ± 62.91 | -0.3 ± 62.06 |
| Urate, Week 4, n=32, 34, 33, 37, 29, 30 | -12.5 ± 34.36 | -7.9 ± 43.82 | 11.2 ± 48.01 | 5.7 ± 49.36 | -10.7 ± 54.11 | 2.7 ± 52.06 |
| Urate, Week 8, n=30, 31, 32, 37, 27, 26 | -5.0 ± 37.30 | -8.7 ± 37.13 | -3.8 ± 32.30 | -0.3 ± 45.43 | -6.3 ± 73.54 | -4.2 ± 75.80 |
| Urate, Week 12, n=27, 30, 32, 36, 26, 24 | -6.3 ± 28.44 | 5.7 ± 34.51 | 1.6 ± 35.21 | -1.7 ± 55.01 | 0.4 ± 88.79 | 15.4 ± 66.27 |
| Urate, Week 14, n=29, 31, 33, 34, 27, 24 | 3.1 ± 41.15 | 19.4 ± 71.04 | 16.4 ± 48.98 | -5.9 ± 54.72 | -14.1 ± 59.37 | -2.5 ± 65.62 |
| Urate, EW, n=10, 6, 3, 2, 10, 9 | -2.0 ± 35.21 | -38.3 ± 31.89 | 76.7 ± 98.15 | -10.0 ± 14.14 | -13.0 ± 33.68 | -13.3 ± 52.92 |
Blood samples were collected for the evaluation of change in levels of calcium, chloride, CO2, glucose, potassium, sodium, and urea from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| millimoles (mmol)/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Calcium, Week 2, n=35, 36, 35, 37, 29, 34 | -0.036 ± 0.1241 | -0.036 ± 0.0935 | -0.041 ± 0.1411 | -0.036 ± 0.0967 | -0.048 ± 0.1239 | -0.006 ± 0.0887 |
| Calcium, Week 4, n=32, 34, 33, 37, 29, 30 | -0.037 ± 0.1003 | -0.045 ± 0.0788 | -0.033 ± 0.1306 | -0.014 ± 0.0899 | -0.036 ± 0.1451 | 0.003 ± 0.0830 |
| Calcium, Week 8, n=30, 31, 32, 37, 27, 26 | -0.034 ± 0.1205 | -0.015 ± 0.0853 | -0.036 ± 0.0951 | -0.010 ± 0.1000 | -0.039 ± 0.1131 | -0.017 ± 0.0948 |
| Calcium, Week 12, n=27, 30, 32, 36, 26, 24 | -0.019 ± 0.0910 | -0.013 ± 0.0934 | -0.034 ± 0.0845 | -0.021 ± 0.1129 | -0.032 ± 0.0988 | 0.011 ± 0.1127 |
| Calcium, Week 14, n=29, 31, 33, 34, 27, 24 | -0.028 ± 0.0912 | -0.030 ± 0.1067 | -0.029 ± 0.0930 | -0.025 ± 0.0935 | -0.045 ± 0.1270 | -0.020 ± 0.1052 |
| Calcium, EW, n=10, 6, 3, 2, 10, 9 | -0.024 ± 0.0717 | -0.020 ± 0.0632 | 0.007 ± 0.1286 | -0.030 ± 0.0990 | -0.014 ± 0.0366 | 0.004 ± 0.0691 |
| Chloride, Week 2, n=35, 36, 35, 37, 29, 34 | -0.1 ± 2.30 | 0.3 ± 2.00 | -0.3 ± 1.98 | 0.1 ± 2.05 | 0.3 ± 2.44 | -0.0 ± 2.29 |
| Chloride, Week 4, n=32, 34, 33, 37, 29, 30 | -0.1 ± 1.66 | 0.5 ± 1.97 | -0.4 ± 2.56 | -0.5 ± 1.83 | 0.1 ± 2.62 | -0.7 ± 2.74 |
| Chloride, Week 8, n=30, 31, 32, 37, 27, 26 | 0.3 ± 1.73 | 0.6 ± 1.89 | -0.3 ± 2.02 | 0.3 ± 2.03 | -0.1 ± 2.13 | -0.3 ± 3.07 |
| Chloride, Week 12, n=27, 30, 32, 36, 26, 24 | -0.4 ± 2.62 | 0.7 ± 2.00 | 0.1 ± 2.29 | -0.2 ± 2.35 | 0.7 ± 2.37 | -0.7 ± 2.80 |
| Chloride, Week 14, n=29, 31, 33, 34, 27, 24 | 0.4 ± 2.24 | 0.5 ± 2.23 | -0.3 ± 2.31 | 0.5 ± 2.30 | -0.3 ± 2.84 | 0.2 ± 2.55 |
| Chloride, EW, n=10, 6, 3, 2, 10, 9 | -0.8 ± 3.19 | -1.5 ± 0.84 | -1.0 ± 2.00 | 1.0 ± 1.41 | 0.0 ± 2.31 | -1.9 ± 2.98 |
| CO2, Week 2, n=35, 36, 35, 37, 29, 34 | -1.6 ± 2.13 | -1.1 ± 2.48 | -1.2 ± 2.64 | -1.2 ± 1.96 | -0.6 ± 2.37 | -0.9 ± 2.04 |
| CO2, Week 4, n=32, 34, 33, 37, 29, 30 | -1.0 ± 2.21 | -1.4 ± 2.57 | -2.0 ± 2.81 | -0.8 ± 2.12 | -0.5 ± 1.99 | -1.5 ± 2.50 |
| CO2, Week 8, n=30, 31, 32, 37, 27, 26 | -1.6 ± 2.19 | -1.5 ± 2.49 | -1.3 ± 1.89 | -1.0 ± 2.25 | -1.0 ± 1.85 | -1.5 ± 2.47 |
| CO2, Week 12, n=27, 30, 32, 36, 26, 24 | -1.0 ± 1.58 | -1.1 ± 1.87 | -1.2 ± 2.55 | -1.1 ± 2.31 | -0.9 ± 2.66 | -1.1 ± 2.23 |
| CO2, Week 14, n=29, 31, 33, 34, 27, 24 | -0.7 ± 2.02 | -0.7 ± 2.55 | -1.0 ± 2.38 | -1.1 ± 2.32 | -0.3 ± 2.31 | -1.2 ± 2.19 |
| CO2, EW, n=10, 6, 3, 2, 10, 9 | -1.7 ± 1.57 | 0.5 ± 1.52 | 0.0 ± 3.46 | 0.0 ± 1.41 | -0.6 ± 1.65 | -0.1 ± 1.27 |
| Glucose, Week 2, n=35, 36, 35, 37, 29, 34 | 0.35 ± 1.147 | 0.59 ± 1.445 | -0.09 ± 1.852 | 0.05 ± 1.864 | -0.01 ± 1.168 | 0.28 ± 1.398 |
| Glucose, Week 4, n=32, 34, 33, 37, 29, 30 | 0.84 ± 1.750 | 0.53 ± 1.656 | 0.40 ± 3.059 | 0.42 ± 2.842 | 0.01 ± 1.299 | 0.73 ± 2.436 |
| Glucose, Week 8, n=30, 31, 32, 37, 27, 26 | 0.32 ± 1.571 | 0.29 ± 1.340 | 0.63 ± 2.604 | 0.35 ± 1.376 | 0.18 ± 1.505 | 0.55 ± 2.392 |
| Glucose, Week 12, n=27, 30, 32, 36, 26, 24 | 0.26 ± 2.223 | -0.33 ± 1.099 | 0.42 ± 2.704 | -0.02 ± 1.977 | -0.24 ± 0.966 | 0.45 ± 1.703 |
| Glucose, Week 14, n=29, 31, 33, 34, 27, 24 | 0.03 ± 1.708 | 0.15 ± 1.628 | 0.79 ± 2.608 | 0.12 ± 2.224 | -0.02 ± 2.104 | 0.13 ± 1.696 |
| Glucose, EW, n=10, 6, 3, 2, 10, 9 | 0.00 ± 1.524 | 0.58 ± 2.185 | 0.43 ± 1.361 | -0.25 ± 0.212 | 0.35 ± 0.357 | 0.37 ± 1.665 |
| Potassium, Week 2, n=35, 36, 35, 37, 29, 34 | 0.07 ± 0.412 | 0.03 ± 0.322 | 0.10 ± 0.450 | 0.12 ± 0.349 | 0.20 ± 0.408 | -0.00 ± 0.306 |
| Potassium, Week 4, n=32, 34, 33, 37, 29, 30 | 0.07 ± 0.382 | 0.09 ± 0.370 | 0.05 ± 0.281 | -0.01 ± 0.307 | 0.13 ± 0.480 | 0.01 ± 0.380 |
| Potassium, Week 8, n=30, 31, 32, 37, 27, 26 | 0.10 ± 0.365 | 0.09 ± 0.576 | 0.06 ± 0.312 | -0.04 ± 0.302 | 0.05 ± 0.377 | 0.10 ± 0.600 |
| Potassium, Week 12, n=27, 30, 32, 36, 26, 24 | -0.07 ± 0.321 | 0.02 ± 0.228 | 0.13 ± 0.395 | 0.00 ± 0.359 | 0.02 ± 0.376 | 0.02 ± 0.298 |
| Potassium, Week 14, n=29, 31, 33, 34, 27, 24 | -0.01 ± 0.274 | 0.02 ± 0.268 | 0.05 ± 0.361 | -0.06 ± 0.319 | -0.01 ± 0.372 | 0.01 ± 0.372 |
| Potassium, EW, n=10, 6, 3, 2, 10, 9 | -0.05 ± 0.217 | -0.02 ± 0.605 | 0.23 ± 0.493 | 0.35 ± 0.071 | -0.15 ± 0.357 | -0.08 ± 0.291 |
| Sodium, Week 2, n=35, 36, 35, 37, 29, 34 | -0.7 ± 2.19 | -0.2 ± 2.04 | -0.2 ± 2.13 | -0.6 ± 2.09 | -0.0 ± 2.21 | -0.5 ± 1.94 |
| Sodium, Week 4, n=32, 34, 33, 37, 29, 30 | -0.6 ± 1.52 | -0.1 ± 1.81 | -1.1 ± 2.28 | -0.8 ± 2.07 | 0.1 ± 2.47 | -1.2 ± 2.06 |
| Sodium, Week 8, n=30, 31, 32, 37, 27, 26 | -0.3 ± 1.86 | -0.2 ± 1.93 | -0.9 ± 2.01 | -0.2 ± 2.25 | -1.1 ± 2.21 | -0.8 ± 2.43 |
| Sodium, Week 12, n=27, 30, 32, 36, 26, 24 | -0.6 ± 2.75 | 0.1 ± 1.93 | -0.3 ± 2.43 | -0.5 ± 1.90 | -0.2 ± 2.60 | -1.2 ± 2.08 |
| Sodium, Week 14, n=29, 31, 33, 34, 27, 24 | -0.3 ± 2.17 | -0.2 ± 1.51 | -0.6 ± 2.18 | -0.7 ± 2.29 | -0.8 ± 2.33 | -1.0 ± 2.30 |
| Sodium, EW, n=10, 6, 3, 2, 10, 9 | -1.4 ± 2.17 | -0.5 ± 1.52 | -1.0 ± 2.65 | 1.0 ± 1.41 | -0.8 ± 2.15 | -2.0 ± 2.06 |
| Urea, Week 2, n=35, 36, 35, 37, 29, 34 | 0.17 ± 1.317 | 0.44 ± 2.242 | 0.06 ± 1.193 | 0.38 ± 1.187 | -0.09 ± 1.044 | 0.10 ± 1.347 |
| Urea, Week 4, n=32, 34, 33, 37, 29, 30 | -0.23 ± 0.907 | 0.41 ± 1.469 | 0.05 ± 1.195 | 0.36 ± 0.991 | -0.19 ± 1.198 | 0.28 ± 1.501 |
| Urea, Week 8, n=30, 31, 32, 37, 27, 26 | -0.07 ± 1.158 | -0.13 ± 1.049 | -0.45 ± 1.310 | 0.32 ± 0.876 | -0.22 ± 1.022 | -0.13 ± 1.179 |
| Urea, Week 12, n=27, 30, 32, 36, 26, 24 | -0.17 ± 0.888 | 0.28 ± 1.201 | -0.27 ± 1.344 | 0.43 ± 1.220 | -0.19 ± 0.861 | -0.15 ± 1.485 |
| Urea, Week 14, n=29, 31, 33, 34, 27, 24 | -0.10 ± 1.105 | 0.55 ± 1.485 | -0.08 ± 1.442 | 0.07 ± 1.303 | 0.35 ± 1.199 | -0.15 ± 1.272 |
| Urea, EW, n=10, 6, 3, 2, 10, 9 | 0.25 ± 1.007 | -0.83 ± 0.983 | 1.83 ± 3.884 | 0.00 ± 1.414 | -0.05 ± 1.012 | 0.28 ± 1.460 |
Blood samples were collected for the evaluation of change in levels of basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Giga unit/liter (GI/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Basophils, Week 2, n=35, 35, 36, 37, 29, 35 | 0.004 ± 0.0213 | -0.005 ± 0.0167 | -0.005 ± 0.0178 | 0.006 ± 0.0243 | 0.003 ± 0.0248 | 0.003 ± 0.0172 |
| Basophils, Week 4, n=31, 34, 35, 37, 29, 31 | 0.003 ± 0.0176 | -0.002 ± 0.0285 | -0.002 ± 0.0166 | -0.003 ± 0.0184 | 0.002 ± 0.0175 | -0.000 ± 0.0143 |
| Basophils, Week 8, n=30, 30, 32, 37, 27, 26 | -0.001 ± 0.0167 | -0.001 ± 0.0181 | -0.004 ± 0.0150 | -0.002 ± 0.0195 | 0.002 ± 0.0233 | -0.008 ± 0.0145 |
| Basophils, Week 12, n=27, 30, 31, 36, 26, 25 | -0.003 ± 0.0151 | 0.004 ± 0.0233 | -0.007 ± 0.0170 | 0.000 ± 0.0161 | 0.006 ± 0.0250 | -0.003 ± 0.0151 |
| Basophils, Week 14, n=29, 30, 33, 34, 27, 23 | -0.003 ± 0.0176 | -0.003 ± 0.0184 | -0.003 ± 0.0188 | 0.002 ± 0.0250 | -0.001 ± 0.0188 | -0.001 ± 0.0216 |
| Basophils, EW, n=10, 6, 3, 2, 10, 9 | -0.001 ± 0.0179 | -0.017 ± 0.0294 | -0.010 ± 0.0100 | 0.000 ± 0.000 | -0.005 ± 0.0151 | 0.012 ± 0.0217 |
| Eosinophils, Week 2, n=35, 35, 36, 37, 29, 35 | 0.021 ± 0.1157 | 0.043 ± 0.1356 | -0.017 ± 0.1857 | 0.011 ± 0.0972 | -0.021 ± 0.1363 | -0.015 ± 0.1295 |
| Eosinophils, Week 4, n=31, 34, 35, 37, 29, 31 | 0.019 ± 0.1380 | 0.034 ± 0.1371 | -0.005 ± 0.1554 | 0.005 ± 0.0954 | -0.019 ± 0.1205 | -0.005 ± 0.1522 |
| Eosinophils, Week 8, n=30, 30, 32, 37, 27, 26 | 0.012 ± 0.1134 | 0.024 ± 0.1015 | -0.008 ± 0.1495 | 0.037 ± 0.1001 | -0.008 ± 0.1142 | -0.048 ± 0.1258 |
| Eosinophils, Week 12, n=27, 30, 31, 36, 26, 25 | 0.047 ± 0.2302 | 0.000 ± 0.1002 | -0.032 ± 0.1714 | 0.026 ± 0.0934 | 0.001 ± 0.1375 | -0.027 ± 0.1322 |
| Eosinophils, Week 14, n=29, 30, 33, 34, 27, 23 | 0.033 ± 0.1084 | 0.004 ± 0.0979 | -0.011 ± 0.2186 | 0.002 ± 0.1053 | 0.004 ± 0.1469 | -0.053 ± 0.1867 |
| Eosinophils, EW, n=10, 6, 3, 2, 10, 9 | 0.029 ± 0.0841 | 0.090 ± 0.1563 | -0.233 ± 0.3955 | 0.095 ± 0.0071 | 0.053 ± 0.2675 | -0.047 ± 0.1775 |
| Lymphocytes, Week 2, n=35, 35, 36, 37, 29, 35 | 0.100 ± 0.4690 | -0.002 ± 0.3827 | 0.097 ± 0.3995 | 0.145 ± 0.3966 | -0.138 ± 0.4764 | -0.018 ± 0.4774 |
| Lymphocytes, Week 4, n=31, 34, 35, 37, 29, 31 | -0.083 ± 0.6201 | -0.044 ± 0.4101 | 0.041 ± 0.3875 | 0.228 ± 0.5664 | -0.142 ± 0.4421 | -0.077 ± 0.4524 |
| Lymphocytes, Week 8, n=30, 30, 32, 37, 27, 26 | 0.048 ± 0.5656 | -0.009 ± 0.3778 | -0.048 ± 0.4379 | 0.075 ± 0.5255 | -0.110 ± 0.6406 | 0.032 ± 0.4913 |
| Lymphocytes, Week 12, n=27, 30, 31, 36, 26, 25 | 0.050 ± 0.6354 | 0.052 ± 0.4589 | 0.120 ± 0.5800 | 0.148 ± 0.4774 | -0.110 ± 0.6003 | -0.145 ± 0.4177 |
| Lymphocytes, Week 14, n=29, 30, 33, 34, 27, 23 | 0.261 ± 0.9065 | 0.021 ± 0.6397 | 0.075 ± 0.5712 | 0.174 ± 0.7327 | -0.031 ± 0.6712 | 0.109 ± 0.4985 |
| Lymphocytes, EW, n=10, 6, 3, 2, 10, 9 | -0.164 ± 0.6069 | -0.078 ± 0.3542 | -0.113 ± 0.3502 | -0.185 ± 0.1061 | 0.032 ± 0.2862 | 0.246 ± 0.4375 |
| Monocytes, Week 2, n=35, 35, 36, 37, 29, 35 | 0.029 ± 0.1833 | -0.061 ± 0.1055 | 0.012 ± 0.1314 | -0.035 ± 0.1117 | -0.007 ± 0.1583 | -0.013 ± 0.1083 |
| Monocytes, Week 4, n=31, 34, 35, 37, 29, 31 | -0.017 ± 0.1241 | -0.014 ± 0.1706 | -0.014 ± 0.1226 | -0.049 ± 0.1119 | -0.032 ± 0.1972 | -0.011 ± 0.1464 |
| Monocytes, Week 8, n=30, 30, 32, 37, 27, 26 | 0.034 ± 0.1468 | -0.071 ± 0.1258 | -0.036 ± 0.1252 | -0.043 ± 0.1579 | -0.048 ± 0.1692 | -0.025 ± 0.1770 |
| Monocytes, Week 12, n=27, 30, 31, 36, 26, 25 | -0.002 ± 0.1173 | -0.050 ± 0.1036 | -0.055 ± 0.1399 | -0.043 ± 0.1578 | -0.015 ± 0.1964 | -0.026 ± 0.1323 |
| Monocytes, Week 14, n=29, 30, 33, 34, 27, 23 | 0.031 ± 0.1418 | -0.009 ± 0.1341 | -0.057 ± 0.1378 | -0.054 ± 0.1609 | -0.025 ± 0.2130 | -0.017 ± 0.1202 |
| Monocytes, EW, n=10, 6, 3, 2, 10, 9 | 0.046 ± 0.1959 | -0.015 ± 0.1299 | -0.243 ± 0.2593 | -0.045 ± 0.1061 | 0.006 ± 0.1179 | -0.084 ± 0.2625 |
| Neutrophils, Week 2, n=35, 35, 36, 37, 29, 35 | 0.355 ± 1.7248 | 0.310 ± 1.3852 | 0.341 ± 1.3914 | 0.009 ± 1.3107 | -0.058 ± 1.8094 | 0.107 ± 1.1007 |
| Neutrophils, Week 4, n=31, 34, 35, 37, 29, 31 | 0.215 ± 1.5812 | 0.139 ± 1.6995 | 0.291 ± 1.2083 | 0.267 ± 1.3310 | 0.049 ± 1.7831 | 0.059 ± 1.0011 |
| Neutrophils, Week 8, n=30, 30, 32, 37, 27, 26 | 0.402 ± 1.1117 | 0.140 ± 1.1014 | -0.049 ± 1.4021 | -0.075 ± 1.4243 | -0.181 ± 1.4359 | 0.285 ± 1.3332 |
| Neutrophils, Week 12, n=27, 30, 31, 36, 26, 25 | 0.277 ± 1.0785 | 0.099 ± 1.3124 | -0.015 ± 1.4752 | -0.008 ± 1.4329 | 0.043 ± 1.3470 | 0.008 ± 1.0432 |
| Neutrophils, Week 14, n=29, 30, 33, 34, 27, 23 | 0.158 ± 1.0726 | 0.519 ± 1.4793 | -0.053 ± 1.0828 | -0.225 ± 1.5059 | 0.267 ± 2.2299 | -0.052 ± 0.8640 |
| Neutrophils, EW, n=10, 6, 3, 2, 10, 9 | 0.307 ± 1.1539 | -0.305 ± 1.3530 | 2.727 ± 3.3561 | -0.735 ± 0.2899 | -0.285 ± 1.2029 | -0.019 ± 0.9601 |
| Platelets, Week 2, n=35, 35, 36, 37, 29, 35 | -0.3 ± 36.30 | 5.4 ± 40.50 | 2.3 ± 26.06 | -5.6 ± 47.57 | 0.5 ± 29.07 | -6.1 ± 23.70 |
| Platelets, Week 4, n=32, 34, 35, 37, 29, 31 | -12.3 ± 39.49 | -4.1 ± 26.64 | 1.9 ± 26.97 | -1.0 ± 38.16 | 2.6 ± 26.00 | -0.7 ± 28.81 |
| Platelets, Week 8, n=30, 31, 32, 38, 27, 26 | -6.8 ± 34.57 | -1.0 ± 23.87 | -1.8 ± 25.81 | -11.5 ± 50.01 | 0.2 ± 28.94 | -1.5 ± 23.61 |
| Platelets, Week 12, n=27, 30, 31, 36, 26, 25 | -10.3 ± 35.25 | -7.9 ± 24.25 | -4.9 ± 26.54 | -15.7 ± 38.39 | -5.5 ± 38.31 | -8.9 ± 26.72 |
| Platelets, Week 14, n=29, 30, 33, 34, 27, 23 | -2.9 ± 18.68 | -9.6 ± 29.12 | -2.9 ± 20.21 | -18.5 ± 41.03 | -1.7 ± 37.21 | 1.2 ± 18.69 |
| Platelets, EW, n=10, 5, 3, 2, 9, 9 | -2.1 ± 27.63 | -7.6 ± 13.89 | 37.0 ± 37.80 | -30.5 ± 48.79 | 1.6 ± 22.36 | 23.1 ± 25.21 |
| Leukocytes, Week 2, n=35, 35, 36, 37, 29, 35 | 0.50 ± 1.834 | 0.28 ± 1.381 | 0.42 ± 1.686 | 0.12 ± 1.391 | -0.21 ± 1.892 | 0.08 ± 1.166 |
| Leukocytes, Week 4, n=31, 34, 35, 37, 29, 31 | 0.13 ± 1.972 | 0.12 ± 1.748 | 0.31 ± 1.374 | 0.44 ± 1.398 | -0.14 ± 1.798 | -0.03 ± 1.059 |
| Leukocytes, Week 8, n=30, 30, 32, 37, 27, 26 | 0.49 ± 1.272 | 0.08 ± 1.167 | -0.14 ± 1.516 | -0.02 ± 1.604 | -0.35 ± 1.392 | 0.23 ± 1.527 |
| Leukocytes, Week 12, n=27, 30, 31, 36, 26, 25 | 0.36 ± 1.439 | 0.12 ± 1.359 | 0.02 ± 1.460 | 0.10 ± 1.538 | -0.07 ± 1.301 | -0.19 ± 1.221 |
| Leukocytes, Week 14, n=29, 30, 33, 34, 27, 23 | 0.47 ± 1.472 | 0.54 ± 1.757 | -0.05 ± 1.256 | -0.11 ± 1.380 | 0.22 ± 2.172 | -0.00 ± 1.207 |
| Leukocytes, EW, n=10, 6, 3, 2, 10, 9 | 0.21 ± 1.066 | -0.35 ± 1.395 | 2.13 ± 2.940 | -0.85 ± 0.354 | -0.21 ± 1.260 | 0.10 ± 0.505 |
Blood samples were collected for the evaluation of change in hematocrit levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Proportion of red blood cells in blood | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2, n=35, 35, 36, 37, 29, 35 | 0.0029 ± 0.0198 | -0.0036 ± 0.0243 | -0.0002 ± 0.0251 | -0.0038 ± 0.0193 | -0.0063 ± 0.0243 | 0.0011 ± 0.0217 |
| Week 4, n=32, 34, 35, 37, 29, 31 | 0.0007 ± 0.0227 | -0.0049 ± 0.0238 | 0.0058 ± 0.0283 | -0.0008 ± 0.0269 | 0.0028 ± 0.0291 | 0.0054 ± 0.0239 |
| Week 8, n=30, 31, 32, 38, 27, 26 | 0.0020 ± 0.0273 | 0.0047 ± 0.0274 | -0.0004 ± 0.0288 | -0.0036 ± 0.0342 | 0.0084 ± 0.0284 | 0.0092 ± 0.0319 |
| Week 12, n=27, 30, 31, 36, 26, 25 | 0.0045 ± 0.0238 | 0.0059 ± 0.0275 | 0.0059 ± 0.0235 | -0.0013 ± 0.0202 | 0.0045 ± 0.0225 | 0.0084 ± 0.0286 |
| Week 14, n=29, 30, 33, 34, 27, 23 | 0.0017 ± 0.0259 | -0.0010 ± 0.0274 | 0.0021 ± 0.0288 | -0.0120 ± 0.0348 | -0.0021 ± 0.0336 | 0.0035 ± 0.0186 |
| EW, n=10, 6, 3, 2, 10, 9 | 0.0014 ± 0.0185 | -0.0273 ± 0.0221 | -0.0093 ± 0.0134 | -0.0050 ± 0.0014 | -0.0017 ± 0.0161 | 0.0014 ± 0.0268 |
Blood samples were collected for the evaluation of change in Hgb levels and MCHC from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| G/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Hgb, Week 2, n=35, 35, 36, 37, 29, 35 | 0.3 ± 5.84 | -1.6 ± 6.98 | -1.4 ± 7.51 | -0.6 ± 6.29 | -1.3 ± 7.79 | 0.1 ± 6.18 |
| Hgb, Week 4, n=32, 34, 35, 37, 29, 31 | -1.0 ± 6.02 | -2.5 ± 5.86 | 0.3 ± 8.74 | -0.1 ± 8.82 | -0.7 ± 8.77 | 1.0 ± 5.68 |
| Hgb, Week 8, n=30, 31, 32, 38, 27, 26 | -1.8 ± 6.18 | 0.1 ± 6.78 | -2.8 ± 9.06 | -2.1 ± 9.17 | 1.0 ± 8.82 | 1.2 ± 7.73 |
| Hgb, Week 12, n=27, 30, 31, 36, 26, 25 | -1.3 ± 5.74 | -0.8 ± 6.86 | -1.9 ± 8.76 | -2.4 ± 5.94 | -1.0 ± 7.65 | 0.2 ± 6.27 |
| Hgb, Week 14, n=29, 30, 33, 34, 27, 23 | -1.9 ± 7.85 | -2.7 ± 7.54 | -2.6 ± 8.64 | -5.0 ± 10.24 | -2.8 ± 8.82 | -1.6 ± 5.94 |
| Hgb, EW, n=10, 6, 3, 2, 10, 9 | 0.0 ± 7.26 | -7.8 ± 8.73 | -5.7 ± 3.79 | -1.5 ± 0.71 | -2.3 ± 4.99 | -0.1 ± 6.13 |
| MCHC, Week 2, n=35, 35, 36, 37, 29, 35 | -1.5 ± 8.77 | -1.3 ± 9.44 | -3.0 ± 10.32 | 1.0 ± 7.15 | 0.9 ± 7.99 | -0.5 ± 7.10 |
| MCHC, Week 4, n=32, 34, 35, 37, 29, 31 | -3.1 ± 11.45 | -2.1 ± 9.88 | -3.6 ± 10.60 | 0.4 ± 8.36 | -3.8 ± 9.19 | -1.6 ± 10.02 |
| MCHC, Week 8, n=30, 31, 32, 38, 27, 26 | -5.4 ± 11.25 | -3.2 ± 12.76 | -5.9 ± 13.41 | -2.3 ± 11.29 | -4.4 ± 10.65 | -3.8 ± 11.40 |
| MCHC, Week 12, n=27, 30, 31, 36, 26, 25 | -6.1 ± 12.65 | -6.1 ± 11.25 | -8.6 ± 11.49 | -4.8 ± 10.39 | -5.9 ± 10.14 | -5.0 ± 10.74 |
| MCHC, Week 14, n=29, 30, 33, 34, 27, 23 | -5.4 ± 8.55 | -5.5 ± 9.15 | -7.4 ± 10.74 | -2.7 ± 9.40 | -5.3 ± 9.27 | -5.9 ± 9.79 |
| MCHC, EW, n=10, 6, 3, 2, 10, 9 | -1.1 ± 11.57 | 1.5 ± 8.50 | -6.3 ± 9.07 | 0.0 ± 0.00 | -4.1 ± 4.12 | -1.3 ± 9.10 |
Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular hemoglobin level from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Picogram (pg) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2, n=35, 35, 36, 37, 29, 35 | 0.10 ± 0.493 | 0.05 ± 0.408 | -0.08 ± 0.590 | 0.11 ± 0.733 | -0.10 ± 1.519 | -0.01 ± 0.605 |
| Week 4, n=32, 34, 35, 37, 29, 31 | 0.01 ± 0.562 | -0.06 ± 0.517 | -0.19 ± 0.750 | 0.08 ± 0.774 | -0.15 ± 1.257 | -0.15 ± 0.863 |
| Week 8, n=30, 31, 32, 38, 27, 26 | 0.13 ± 0.608 | 0.31 ± 2.220 | -0.20 ± 0.805 | -0.04 ± 0.803 | -0.13 ± 1.286 | -0.09 ± 0.753 |
| Week 12, n=27, 30, 31, 36, 26, 25 | 0.20 ± 0.804 | -0.07 ± 0.672 | -0.15 ± 0.532 | -0.00 ± 0.837 | -0.30 ± 1.265 | -0.21 ± 0.764 |
| Week 14, n=29, 30, 33, 34, 27, 23 | 0.39 ± 0.671 | 0.02 ± 0.406 | -0.19 ± 0.685 | 0.07 ± 0.785 | -0.23 ± 1.396 | 0.01 ± 0.557 |
| EW, n=10, 6, 3, 2, 10, 9 | 0.10 ± 0.371 | 0.15 ± 0.734 | -0.50 ± 0.520 | 0.05 ± 0.071 | -0.02 ± 0.181 | -0.12 ± 0.533 |
Blood samples were collected for the evaluation of change in erythrocyte mean corpuscular volume from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Femtoliter (fL) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2, n=35, 35, 36, 37, 29, 35 | 0.7 ± 2.38 | 0.6 ± 2.07 | 0.6 ± 2.39 | 0.1 ± 2.11 | -0.5 ± 4.05 | 0.2 ± 1.96 |
| Week 4, n=32, 34, 35, 37, 29, 31 | 0.8 ± 2.21 | 0.4 ± 1.94 | 0.4 ± 2.65 | 0.2 ± 2.39 | 0.7 ± 3.73 | 0.0 ± 3.10 |
| Week 8, n=30, 31, 32, 38, 27, 26 | 2.0 ± 2.39 | 2.0 ± 5.05 | 1.1 ± 3.57 | 0.6 ± 3.41 | 0.9 ± 3.80 | 0.9 ± 3.10 |
| Week 12, n=27, 30, 31, 36, 26, 25 | 2.4 ± 2.27 | 1.6 ± 1.94 | 1.9 ± 3.41 | 1.4 ± 3.72 | 0.8 ± 3.98 | 0.9 ± 2.93 |
| Week 14, n=29, 30, 33, 34, 27, 23 | 2.7 ± 2.87 | 1.6 ± 2.08 | 1.5 ± 3.04 | 0.9 ± 3.27 | 0.9 ± 3.95 | 1.9 ± 2.36 |
| EW, n=10, 6, 3, 2, 10, 9 | 0.6 ± 3.41 | 0.0 ± 2.19 | -0.3 ± 0.58 | -0.5 ± 0.71 | 1.1 ± 1.60 | 0.1 ± 2.42 |
Blood samples were collected for the evaluation of change in erythrocyte count from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Tetra unit/L (TI/L) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 2, n=35, 35, 36, 37, 29, 35 | -0.01 ± 0.180 | -0.06 ± 0.243 | -0.04 ± 0.315 | -0.05 ± 0.210 | -0.03 ± 0.363 | 0.01 ± 0.269 |
| Week 4, n=32, 34, 35, 37, 29, 31 | -0.03 ± 0.213 | -0.06 ± 0.220 | 0.02 ± 0.358 | -0.01 ± 0.269 | 0.01 ± 0.421 | 0.05 ± 0.294 |
| Week 8, n=30, 31, 32, 38, 27, 26 | -0.09 ± 0.273 | -0.05 ± 0.468 | -0.07 ± 0.306 | -0.07 ± 0.257 | 0.06 ± 0.356 | 0.03 ± 0.317 |
| Week 12, n=27, 30, 31, 36, 26, 25 | -0.07 ± 0.237 | 0.00 ± 0.257 | -0.05 ± 0.356 | -0.08 ± 0.228 | 0.00 ± 0.328 | 0.04 ± 0.229 |
| Week 14, n=29, 30, 33, 34, 27, 23 | -0.13 ± 0.334 | -0.09 ± 0.252 | -0.07 ± 0.374 | -0.18 ± 0.343 | -0.06 ± 0.370 | -0.07 ± 0.194 |
| EW, n=10, 6, 3, 2, 10, 9 | -0.03 ± 0.250 | -0.30 ± 0.268 | -0.13 ± 0.153 | -0.10 ± 0.000 | -0.07 ± 0.200 | 0.00 ± 0.212 |
Blood samples were collected for the evaluation of clinical chemistry parameters including alk phos, ALT, AST, bil, calcium, CO2, creatinine, glucose and potassium. The number of participants with chemistry data of potential clinical importance for the mentioned parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Alk. Phos, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk. Phos, Week 2, n=35, 36, 35, 37, 29, 34 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk. Phos, Week 4, n=32, 34, 33, 37, 29, 30 | 0 | 0 | 1 | 0 | 0 | 0 |
| Alk. Phos, Week 8, n=30, 31, 32, 37, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk. Phos, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk. Phos, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk. Phos, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Alk. Phos,post-screen(PS),n=38, 37, 37, 38, 36, 36 | 0 | 0 | 1 | 0 | 0 | 0 |
| ALT, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, Week 2, n=35, 36, 35, 37, 29, 34 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT, Week 4, n=32, 34, 33, 37, 29, 30 | 1 | 0 | 0 | 0 | 0 | 1 |
| ALT, Week 8, n=30, 31, 32, 37, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 0 | 0 | 0 | 1 |
| ALT, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALT, PS, n=38, 37, 37, 38, 36, 36 | 1 | 0 | 0 | 0 | 0 | 2 |
| AST, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 1 | 0 | 0 | 0 | 0 |
| AST, Week 2, n=35, 36, 35, 37, 29, 34 | 0 | 1 | 0 | 0 | 0 | 0 |
| AST, Week 4, n=32, 34, 33, 37, 29, 30 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, Week 8, n=30, 31, 32, 37, 27, 26 | 0 | 1 | 0 | 0 | 0 | 0 |
| AST, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| AST, PS, n=38, 37, 37, 38, 36, 36 | 0 | 2 | 0 | 0 | 0 | 0 |
| Bil, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 1 |
| Bil, Week 2, n=35, 36, 35, 37, 29, 34 | 0 | 0 | 0 | 0 | 1 | 1 |
| Bil, Week 4, n=32, 34, 33, 37, 29, 30 | 0 | 0 | 0 | 0 | 0 | 1 |
| Bil, Week 8, n=30, 31, 32, 37, 27, 26 | 0 | 0 | 0 | 0 | 0 | 1 |
| Bil, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 0 | 0 | 0 | 1 |
| Bil, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 0 | 0 | 0 | 1 |
| Bil, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bil, PS, n=38, 37, 37, 38, 36, 36 | 0 | 0 | 0 | 0 | 1 | 1 |
| Calcium, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, Week 2, n=35, 36, 35, 37, 29, 34 | 0 | 0 | 1 | 0 | 0 | 0 |
| Calcium, Week 4, n=32, 34, 33, 37, 29, 30 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, Week 8, n=30, 31, 32, 37, 27, 26 | 0 | 0 | 1 | 0 | 0 | 0 |
| Calcium, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 0 | 1 | 0 | 0 |
| Calcium, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Calcium, PS, n=38, 37, 37, 38, 36, 36 | 0 | 0 | 2 | 1 | 0 | 0 |
| CO2, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 1 | 0 | 0 | 0 |
| CO2, Week 2, n=35, 36, 35, 37, 29, 34 | 1 | 0 | 4 | 1 | 0 | 0 |
| CO2, Week 4, n=32, 34, 33, 37, 29, 30 | 0 | 1 | 3 | 0 | 0 | 0 |
| CO2, Week 8, n=30, 31, 32, 37, 27, 26 | 1 | 1 | 1 | 0 | 0 | 0 |
| CO2, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 3 | 1 | 0 | 0 |
| CO2, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 1 | 1 | 0 | 0 |
| CO2, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| CO2, PS, n=38, 37, 37, 38, 36, 36 | 1 | 1 | 8 | 2 | 0 | 0 |
| Creatinine, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, Week 2, n=35, 36, 35, 37, 29, 34 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, Week 4, n=32, 34, 33, 37, 29, 30 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, Week 8, n=30, 31, 32, 37, 27, 26 | 0 | 0 | 0 | 1 | 0 | 0 |
| Creatinine, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| Creatinine, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 1 | 0 | 0 | 0 |
| Creatinine, PS, n=38, 37, 37, 38, 36, 36 | 0 | 0 | 1 | 1 | 0 | 0 |
| Glucose, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 4 | 5 | 2 | 5 | 1 |
| Glucose, Week 2, n=35, 36, 35, 37, 29, 34 | 2 | 5 | 5 | 2 | 2 | 2 |
| Glucose, Week 4, n=32, 34, 33, 37, 29, 30 | 4 | 4 | 4 | 3 | 5 | 3 |
| Glucose, Week 8, n=30, 31, 32, 37, 27, 26 | 1 | 3 | 6 | 2 | 4 | 3 |
| Glucose, Week 12, n=27, 30, 32, 36, 26, 24 | 3 | 3 | 7 | 4 | 2 | 2 |
| Glucose, Week 14, n=29, 31, 33, 34, 27, 24 | 1 | 2 | 7 | 4 | 5 | 3 |
| Glucose, EW, n=10, 6, 3, 2, 10, 9 | 1 | 0 | 0 | 0 | 0 | 0 |
| Glucose, PS, n=38, 37, 37, 38, 36, 36 | 7 | 7 | 7 | 8 | 6 | 9 |
| Potassium, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, Week 2, n=35, 36, 35, 37, 29, 34 | 0 | 0 | 1 | 0 | 1 | 0 |
| Potassium, Week 4, n=32, 34, 33, 37, 29, 30 | 1 | 0 | 0 | 0 | 2 | 1 |
| Potassium, Week 8, n=30, 31, 32, 37, 27, 26 | 0 | 1 | 0 | 0 | 0 | 2 |
| Potassium, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 0 | 1 | 0 | 0 | 0 |
| Potassium, Week 14, n=29, 31, 33, 34, 27, 24 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Potassium, PS, n=38, 37, 37, 38, 36, 36 | 1 | 1 | 1 | 0 | 2 | 2 |
Blood samples were collected for the evaluation of hematology parameters including hematocrit, Hgb, lymphocytes, neutrophils and platelets. The number of participants with clinically significant abnormal values of the mentioned hematology parameters was presented. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Hematocrit,Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 2 | 0 | 0 |
| Hematocrit, Week 2, n=35, 35, 36, 37, 29, 35 | 1 | 0 | 0 | 2 | 0 | 0 |
| Hematocrit, Week 4, n=32, 34, 35, 37, 29, 31 | 0 | 0 | 1 | 2 | 0 | 0 |
| Hematocrit, Week 8, n=30, 31, 32, 38, 27, 26 | 0 | 0 | 0 | 2 | 0 | 1 |
| Hematocrit, Week 12, n=27, 30, 31, 36, 26, 25 | 0 | 0 | 0 | 2 | 0 | 0 |
| Hematocrit, Week 14, n=29, 30, 33, 34, 27, 23 | 1 | 0 | 0 | 1 | 1 | 0 |
| Hematocrit, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hematocrit, PS, n=38, 37, 37, 38, 36, 36 | 2 | 0 | 1 | 3 | 1 | 1 |
| Hgb,Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hgb, Week 2, n=35, 35, 36, 37, 29, 35 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hgb, Week 4, n=32, 34, 35, 37, 29, 31 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hgb, Week 8, n=30, 31, 32, 38, 27, 26 | 0 | 0 | 0 | 2 | 0 | 0 |
| Hgb, Week 12, n=27, 30, 31, 36, 26, 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hgb, Week 14, n=29, 30, 33, 34, 27, 23 | 1 | 0 | 0 | 1 | 0 | 0 |
| Hgb, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hgb, PS, n=38, 37, 37, 38, 36, 36 | 1 | 0 | 0 | 2 | 0 | 0 |
| Lymphocytes, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, Week 2, n=35, 35, 36, 37, 29, 35 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lymphocytes, Week 4, n=31, 34, 35, 37, 29, 31 | 0 | 1 | 0 | 0 | 0 | 1 |
| Lymphocytes, Week 8, n=30, 30, 32, 37, 27, 26 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lymphocytes, Week 12, n=27, 30, 31, 36, 26, 25 | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphocytes, Week 14, n=29, 30, 33, 34, 27, 23 | 0 | 1 | 0 | 0 | 0 | 0 |
| Lymphocytes, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, PS, n=38, 37, 37, 38, 36, 36 | 0 | 1 | 0 | 0 | 1 | 1 |
| Neutrophils,Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 1 | 0 | 0 | 0 |
| Neutrophils, Week 2, n=35, 35, 36, 37, 29, 35 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Week 4, n=31, 34, 35, 37, 29, 31 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Week 8, n=30, 30, 32, 37, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Week 12, n=27, 30, 31, 36, 26, 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Week 14, n=29, 30, 33, 34, 27, 23 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, EW, n=10, 6, 3, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, PS, n=38, 37, 37, 38, 36, 36 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets,Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 1 | 0 | 0 | 0 | 0 |
| Platelets, Week 2, n=35, 35, 36, 37, 29, 35 | 0 | 1 | 0 | 0 | 0 | 0 |
| Platelets, Week 4, n=32, 34, 35, 37, 29, 31 | 0 | 0 | 0 | 0 | 1 | 0 |
| Platelets, Week 8, n=30, 31, 32, 38, 27, 26 | 0 | 0 | 0 | 0 | 1 | 0 |
| Platelets, Week 12, n=27, 30, 31, 36, 26, 25 | 0 | 0 | 0 | 0 | 1 | 0 |
| Platelets, Week 14, n=29, 30, 33, 34, 27, 23 | 0 | 0 | 0 | 0 | 0 | 0 |
| Platelets, EW, n=10, 5, 3, 2, 9, 9 | 0 | 1 | 0 | 0 | 0 | 0 |
| Platelets, PS, n=38, 37, 37, 38, 35, 36 | 0 | 1 | 0 | 0 | 1 | 0 |
Blood samples were collected for the evaluation of change in IgA, IgG and IgM levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| g/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| IgA, Week 4, n=32, 34, 35, 38, 29, 31 | -0.035 ± 0.2151 | -0.138 ± 0.3147 | -0.153 ± 0.5744 | -0.024 ± 0.6150 | 0.125 ± 0.5462 | 0.006 ± 0.2350 |
| IgA, Week 8, n=30, 31, 33, 38, 27, 26 | 0.021 ± 0.3615 | -0.151 ± 0.3497 | -0.239 ± 0.6447 | -0.064 ± 0.6353 | 0.086 ± 0.6911 | -0.050 ± 0.4347 |
| IgA, Week 12, n=27, 30, 32, 36, 26, 24 | -0.028 ± 0.2806 | -0.138 ± 0.2461 | -0.271 ± 0.6764 | -0.037 ± 1.0705 | -0.023 ± 0.8912 | -0.018 ± 0.2355 |
| IgG, Week 4, n=32, 34, 35, 38, 29, 31 | 0.130 ± 0.8150 | -0.223 ± 1.0422 | 0.117 ± 1.4003 | 0.028 ± 1.7157 | 0.441 ± 1.6655 | 0.218 ± 1.1025 |
| IgG, Week 8, n=30, 31, 33, 38, 27, 26 | -0.098 ± 1.1559 | -0.055 ± 1.1243 | -0.016 ± 1.4066 | 0.195 ± 1.4330 | 0.634 ± 1.4913 | 0.299 ± 1.3855 |
| IgG, Week 12, n=27, 30, 32, 36, 26, 24 | 0.248 ± 0.8937 | 0.029 ± 1.1145 | -0.360 ± 1.3683 | 0.251 ± 1.4115 | 0.377 ± 2.0539 | 0.283 ± 1.0979 |
| IgM, Week 4, n=32, 34, 35, 38, 29, 31 | -0.077 ± 0.1215 | -0.050 ± 0.0797 | -0.023 ± 0.3524 | -0.017 ± 0.1434 | -0.004 ± 0.1951 | -0.016 ± 0.1371 |
| IgM, Week 8, n=30, 31, 33, 38, 27, 26 | -0.103 ± 0.1649 | -0.030 ± 0.1737 | -0.005 ± 0.4892 | -0.012 ± 0.1213 | -0.011 ± 0.1951 | -0.006 ± 0.1802 |
| IgM, Week 12, n=27, 30, 32, 36, 26, 24 | -0.072 ± 0.0992 | -0.082 ± 0.1264 | -0.047 ± 0.5307 | -0.017 ± 0.1495 | -0.023 ± 0.2431 | -0.033 ± 0.1900 |
Blood samples were collected for the evaluation of change in Ig levels from Baseline throughout the study. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| IgA, Baseline, n=38, 38, 38, 38, 37, 38 | 2 | 1 | 3 | 4 | 2 | 2 |
| IgA, Week 4, n=32, 34, 35, 38, 29, 31 | 1 | 1 | 1 | 2 | 2 | 1 |
| IgA, Week 8, n=30, 31, 33, 38, 27, 26 | 1 | 1 | 1 | 2 | 1 | 1 |
| IgA, Week 12, n=27, 30, 32, 36, 26, 24 | 0 | 1 | 2 | 3 | 0 | 1 |
| IgA, PS, n=33, 34, 36, 38, 29, 31 | 2 | 1 | 2 | 3 | 2 | 1 |
| IgG, Baseline, n=38, 38, 38, 38, 37, 38 | 4 | 2 | 3 | 2 | 1 | 4 |
| IgG, Week 4, n=32, 34, 35, 38, 29, 31 | 3 | 2 | 3 | 3 | 0 | 4 |
| IgG, Week 8, n=30, 31, 33, 38, 27, 26 | 3 | 2 | 4 | 2 | 1 | 4 |
| IgG, Week 12, n=27, 30, 32, 36, 26, 24 | 2 | 1 | 4 | 4 | 1 | 2 |
| IgG, PS, n=33, 34, 36, 38, 29, 31 | 3 | 2 | 5 | 4 | 1 | 4 |
| IgM, Baseline, n=38, 38, 38, 38, 37, 38 | 11 | 5 | 9 | 3 | 2 | 5 |
| IgM, Week 4, n=32, 34, 35, 38, 29, 31 | 9 | 5 | 9 | 4 | 2 | 3 |
| IgM, Week 8, n=30, 31, 33, 38, 27, 26 | 9 | 6 | 8 | 4 | 2 | 4 |
| IgM, Week 12, n=27, 30, 32, 36, 26, 24 | 8 | 5 | 8 | 3 | 2 | 2 |
| IgM, PS, n=33, 34, 36, 38, 29, 31 | 11 | 6 | 10 | 5 | 3 | 4 |
Blood samples were collected for the evaluation of change in levels of cluster of differentiation (CD)19, CD3, CD3 Treg flow cytometry (CD3TFLC), CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T Cell B Cell Natural Killer Lymphocytes flow cytometry (T-B cell NKL). Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| CD19, Baseline, n=38, 38, 38, 38, 37, 38 | 5 | 5 | 5 | 7 | 11 | 1 |
| CD19, Week 4, n=30, 32, 35, 38, 29, 30 | 2 | 6 | 4 | 6 | 6 | 3 |
| CD19, Week 8, n=30, 31, 33, 38, 27, 26 | 4 | 5 | 6 | 6 | 5 | 2 |
| CD19, Week 12, n=27, 29, 32, 36, 26, 24 | 2 | 4 | 4 | 4 | 6 | 1 |
| CD19, PS, n=33, 34, 36, 38, 29, 31 | 5 | 7 | 8 | 7 | 9 | 4 |
| CD3, Baseline, n=38, 38, 38, 38, 37, 38 | 4 | 3 | 5 | 3 | 1 | 2 |
| CD3, Week 4, n=30, 32, 35, 38, 29, 30 | 1 | 1 | 4 | 0 | 0 | 2 |
| CD3, Week 8, n=30, 31, 33, 38, 27, 26 | 2 | 1 | 4 | 2 | 1 | 2 |
| CD3, Week 12, n=27, 29, 32, 36, 26, 24 | 1 | 2 | 3 | 2 | 2 | 0 |
| CD3, PS, n=33, 34, 36, 38, 29, 31 | 3 | 4 | 8 | 3 | 2 | 3 |
| CD3 TFLC, Baseline, n=37,36,38, 38, 36, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3 TFLC, Week 4, n=28, 30, 32, 36, 28, 26 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3 TFLC, Week 8, n=30, 29, 31, 34, 25, 22 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3 TFLC, Week 12, n=26,26,30, 34, 24, 24 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3 TFLC, PS, n=33, 33, 36, 38, 29, 31 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3+CD8+, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 4 | 2 | 3 | 3 | 5 |
| CD3+CD8+, Week 4, n=30, 32, 35, 38, 29, 30 | 0 | 3 | 3 | 2 | 0 | 3 |
| CD3+CD8+, Week 8, n=30, 31, 33, 38, 27, 26 | 0 | 3 | 0 | 1 | 3 | 3 |
| CD3+CD8+, Week 12, n=27, 29, 32, 36, 26, 24 | 0 | 2 | 0 | 1 | 2 | 2 |
| CD3+CD8+, PS, n=33, 34, 36, 38, 29, 31 | 0 | 4 | 3 | 3 | 3 | 5 |
| CD3+CD8+ TFLC, Baseline, n=37, 36, 38, 38, 36, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD8+ TFLC, Week 4, n=28, 30, 32, 36, 28, 36 | 0 | 1 | 0 | 0 | 1 | 0 |
| CD3+CD8+ TFLC, Week 8, n=30, 29, 31, 34, 25, 22 | 0 | 1 | 0 | 1 | 1 | 0 |
| CD3+CD8+ TFLC, Week 12, n=26, 26, 30, 34, 24, 24 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3+CD8+TFLC, PS, n=33, 33,36, 38, 29, 31 | 0 | 1 | 1 | 2 | 2 | 0 |
| CD3+CD4+, Baseline, n=38, 38, 38, 38, 37, 38 | 6 | 5 | 4 | 2 | 2 | 1 |
| CD3+CD4+, Week 4, n=30, 32, 35, 38, 29, 30 | 3 | 1 | 5 | 3 | 1 | 3 |
| CD3+CD4+, Week 8, n=30, 31, 33, 38, 27, 26 | 3 | 3 | 3 | 2 | 2 | 1 |
| CD3+CD4+, Week 12, n=27, 29, 32, 36, 26, 24 | 1 | 2 | 4 | 2 | 1 | 0 |
| CD3+CD4+, PS, n=33, 34, 36, 38, 29, 31 | 5 | 6 | 8 | 5 | 5 | 3 |
| CD3+CD4+ TFLC, Baseline, n=37, 36, 38, 38, 36, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+ TFLC, Week 4, n=28, 30, 32, 36, 28, 36 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3+CD4+ TFLC, Week 8, n=30, 29, 31, 34, 25, 22 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3+CD4+ TFLC, Week 12, n=26, 26, 30, 34, 24, 24 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD3+CD4+ TF, PS, n=33, 33, 36, 38, 29, 31 | 0 | 1 | 0 | 0 | 0 | 0 |
| CD16+CD56+, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 1 | 0 | 1 |
| CD16+CD56+, Week 4, n=30, 32, 35, 38, 29, 30 | 1 | 0 | 0 | 0 | 0 | 1 |
| CD16+CD56+, Week 8, n=30, 31, 33, 38, 27, 26 | 0 | 0 | 0 | 0 | 1 | 1 |
| CD16+CD56+, Week 12, n=27, 29, 32, 36, 26, 24 | 1 | 0 | 0 | 0 | 0 | 1 |
| CD16+CD56+, PS, n=33, 34, 36, 38, 29, 31 | 1 | 0 | 1 | 2 | 1 | 1 |
| CD3+CD4+CD25+CD127, Baseline, n=37,36,38,38,36,38 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+CD25+CD127, Week 4, n=28,30,32,36,28,36 | 1 | 3 | 1 | 3 | 5 | 0 |
| CD3+CD4+CD25+CD127, Week 8, n=30,29,31,34,25,22 | 0 | 4 | 1 | 2 | 5 | 0 |
| CD3+CD4+CD25+CD127, Week 12, n=26,26,30,34,24,24 | 0 | 6 | 1 | 7 | 5 | 0 |
| CD3+CD4+CD25+CD127, PS, n=33,33,36,38,29,31 | 1 | 7 | 1 | 9 | 7 | 2 |
| CD3+CD4+fP3+CD25+CD127Baseline,n=37,36,38,38,36,38 | 0 | 0 | 0 | 0 | 0 | 0 |
| CD3+CD4+fP3+CD25+CD127, Week 4,n=28,30,32,36,28,36 | 5 | 8 | 4 | 5 | 7 | 3 |
| CD3+CD4+fP3+CD25+CD127, Week 8,n=30,29,31,34,25,22 | 6 | 7 | 6 | 6 | 5 | 4 |
| CD3+CD4+fP3+CD25+CD127 Week 12,n=26,26,30,34,24,24 | 4 | 6 | 3 | 8 | 2 | 2 |
| CD3+CD4+fP3+CD25+CD127, PS,n=33,33,36,38,29,31 | 11 | 14 | 12 | 15 | 11 | 7 |
| T-B cell NKL, Baseline, n=38,38,38,38,37,38 | 1 | 1 | 0 | 1 | 1 | 0 |
| T-B cell NKL, Week 4, n=30,32,35,38,29,30 | 0 | 1 | 1 | 0 | 0 | 1 |
| T-B cell NKL, Week 8, n=30,31,33,38,27,26 | 0 | 0 | 1 | 0 | 0 | 1 |
| T-B cell NKL, Week 12, n=27,29,32,36,26,24 | 0 | 0 | 0 | 0 | 1 | 0 |
| T-B cell NKL, PS, n=33,34,36,38,29,31 | 0 | 1 | 2 | 0 | 1 | 1 |
Blood samples were collected for the evaluation of change from Baseline in immunophenotype levels including CD19, CD3, CD3TFLC, CD3+CD8+, CD3+CD8+ TFLC, CD3+CD4+, CD3+CD4+ TFLC, CD16+CD56+, CD3+CD4+CD25+CD127 flow cytometry (CD3+CD4+CD25+CD127), CD3+CD4+foxP3+CD25+CD127 flow cytometry (CD3+CD4+fP3+CD25+CD127) and T-B cell NKL. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| GI/L | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| CD19, Week 4, n=30, 32, 35, 38, 29, 30 | -0.0182 ± 0.1060 | 0.0318 ± 0.1046 | -0.0261 ± 0.1177 | -0.0184 ± 0.2460 | -0.0241 ± 0.3210 | -0.0109 ± 0.0659 |
| CD19, Week 8, n=30, 31, 33, 38, 27, 26 | 0.0367 ± 0.1284 | 0.0491 ± 0.0984 | -0.0288 ± 0.0953 | -0.0464 ± 0.2220 | -0.0533 ± 0.2878 | 0.0150 ± 0.1099 |
| CD19, Week 12, n=27, 29, 32, 36, 26, 24 | 0.0059 ± 0.1178 | 0.0362 ± 0.0968 | -0.0334 ± 0.0968 | -0.0305 ± 0.2591 | -0.0443 ± 0.2863 | -0.0097 ± 0.0774 |
| CD3, Week 4, n=30, 32, 35, 38, 29, 30 | -0.1067 ± 0.3964 | 0.1044 ± 0.3945 | -0.0360 ± 0.3419 | 0.0186 ± 0.3417 | -0.0842 ± 0.2888 | -0.0584 ± 0.3175 |
| CD3, Week 8, n=30, 31, 33, 38, 27, 26 | 0.0227 ± 0.4318 | 0.1426 ± 0.3650 | -0.0101 ± 0.3231 | -0.0053 ± 0.3463 | -0.1063 ± 0.4996 | -0.0213 ± 0.2936 |
| CD3, Week 12, n=27, 29, 32, 36, 26, 24 | -0.0511 ± 0.4225 | 0.1327 ± 0.4230 | -0.0248 ± 0.3140 | -0.0315 ± 0.3259 | -0.0822 ± 0.3222 | -0.0142 ± 0.3345 |
| CD3 TFLC, Week 4, n=27, 29, 32, 36, 28, 26 | -0.0829 ± 0.4002 | 0.1270 ± 0.4233 | 0.0196 ± 0.3104 | 0.0320 ± 0.3412 | -0.0937 ± 0.3115 | -0.1031 ± 0.3504 |
| CD3 TFLC, Week 8, n=29, 27, 31, 34, 25, 22 | 0.0187 ± 0.4749 | 0.1296 ± 0.3352 | -0.0158 ± 0.3503 | 0.0053 ± 0.2782 | -0.1393 ± 0.5368 | -0.0383 ± 0.3471 |
| CD3 TFLC, Week 12, n=25,24,30, 34, 24, 24 | -0.0916 ± 0.4466 | 0.1494 ± 0.4745 | -0.0266 ± 0.3227 | -0.0342 ± 0.3157 | -0.1220 ± 0.3010 | -0.0280 ± 0.3630 |
| CD3+CD8+, Week 4, n=30, 32, 35, 38, 29, 30 | -0.0297 ± 0.1394 | 0.0524 ± 0.1516 | 0.0094 ± 0.1279 | 0.0095 ± 0.1217 | -0.0009 ± 0.1871 | 0.0179 ± 0.1504 |
| CD3+CD8+, Week 8, n=30, 31, 33, 38, 27, 26 | 0.0001 ± 0.1582 | 0.0683 ± 0.1697 | 0.0100 ± 0.1006 | 0.0219 ± 0.1550 | -0.0189 ± 0.2073 | 0.0566 ± 0.1508 |
| CD3+CD8+, Week 12, n=27, 29, 32, 36, 26, 24 | -0.0174 ± 0.1417 | 0.0477 ± 0.1642 | 0.0106 ± 0.1253 | 0.0151 ± 0.1594 | 0.0081 ± 0.1920 | 0.0326 ± 0.1690 |
| CD3+CD8+ TFLC, Week 4, n=27, 29, 32, 36, 28, 26 | -0.0203 ± 0.1264 | 0.0359 ± 0.1719 | 0.0083 ± 0.0980 | -0.0069 ± 0.1480 | -0.0107 ± 0.1759 | -0.0180 ± 0.1055 |
| CD3+CD8+ TFLC, Week 8, n=29, 27, 31, 34, 25, 22 | -0.0066 ± 0.1420 | 0.0375 ± 0.1628 | 0.0091 ± 0.0920 | 0.0035 ± 0.1194 | -0.0254 ± 0.2065 | 0.0139 ± 0.1195 |
| CD3+CD8+ TFLC, Week 12, n=25, 24, 30, 34, 24, 24 | -0.0306 ± 0.1284 | 0.0260 ± 0.1760 | -0.0042 ± 0.1113 | 0.0010 ± 0.1518 | -0.0112 ± 0.1493 | 0.0193 ± 0.1535 |
| CD3+CD4+, Week 4, n=30, 32, 35, 38, 29, 30 | -0.0750 ± 0.2756 | 0.0525 ± 0.2577 | -0.0374 ± 0.2429 | 0.0210 ± 0.2475 | -0.0857 ± 0.1802 | -0.0775 ± 0.2286 |
| CD3+CD4+, Week 8, n=30, 31, 33, 38, 27, 26 | 0.0296 ± 0.3006 | 0.0758 ± 0.2036 | -0.0042 ± 0.2396 | -0.0164 ± 0.2338 | -0.0821 ± 0.3158 | -0.0715 ± 0.2205 |
| CD3+CD4+, Week 12, n=27, 29, 32, 36, 26, 24 | -0.0228 ± 0.2928 | 0.0936 ± 0.2664 | -0.0225 ± 0.2149 | -0.0249 ± 0.2005 | -0.0798 ± 0.1817 | -0.0458 ± 0.1960 |
| CD3+CD4+ TFLC, Week 4, n=27, 29, 32, 36, 28, 26 | -0.0512 ± 0.2493 | 0.0764 ± 0.2613 | 0.0009 ± 0.2121 | 0.0280 ± 0.2521 | -0.0729 ± 0.1786 | -0.0621 ± 0.2216 |
| CD3+CD4+ TFLC, Week 8, n=29, 27, 31, 34, 25, 22 | 0.0268 ± 0.3134 | 0.0857 ± 0.1814 | -0.0075 ± 0.2525 | 0.0138 ± 0.2066 | -0.0784 ± 0.3136 | -0.0298 ± 0.2089 |
| CD3+CD4+ TFLC, Week 12, n=25, 24, 30, 34, 24, 24 | -0.0511 ± 0.2835 | 0.1196 ± 0.2891 | -0.0159 ± 0.2244 | 0.0044 ± 0.1730 | -0.0679 ± 0.1740 | -0.0386 ± 0.1832 |
| CD16+CD56+, Week 4, n=30, 32, 35, 38, 29, 30 | -0.023 ± 0.0910 | 0.014 ± 0.1031 | 0.011 ± 0.0897 | -0.009 ± 0.0821 | -0.013 ± 0.1134 | 0.001 ± 0.0876 |
| CD16+CD56+, Week 8, n=30, 31, 33, 38, 27, 26 | 0.002 ± 0.0699 | 0.011 ± 0.1312 | 0.009 ± 0.0867 | -0.002 ± 0.0713 | -0.000 ± 0.1800 | 0.013 ± 0.1339 |
| CD16+CD56+, Week 12, n=27, 29, 32, 36, 26, 24 | -0.010 ± 0.0861 | -0.001 ± 0.1283 | -0.015 ± 0.0861 | -0.022 ± 0.1082 | -0.035 ± 0.1168 | 0.024 ± 0.0792 |
| CD3+CD4+CD25+CD127, Week 4, n=27,29,32,36,28,26 | 0.0016 ± 0.0109 | 0.0021 ± 0.0195 | 0.0019 ± 0.0147 | -0.0036 ± 0.0218 | -0.0016 ± 0.0172 | -0.0008 ± 0.0097 |
| CD3+CD4+CD25+CD127, Week 8, n=29,27,31,34,25,22 | 0.0002 ± 0.0141 | 0.0040 ± 0.0228 | 0.0027 ± 0.0133 | -0.0019 ± 0.0200 | -0.0034 ± 0.0205 | 0.0020 ± 0.0122 |
| CD3+CD4+CD25+CD127, Week 12, n=25,24,30,34,24,24 | 0.0060 ± 0.0121 | 0.0035 ± 0.0279 | 0.0029 ± 0.0164 | -0.0035 ± 0.0229 | -0.0037 ± 0.0141 | -0.0010 ± 0.0106 |
| CD3+CD4+fP3+CD25+CD127, Week4,n=27,29,32,36,28,26 | -0.0019 ± 0.0118 | 0.0057 ± 0.0110 | 0.0018 ± 0.0107 | -0.0024 ± 0.0130 | -0.0005 ± 0.0115 | -0.0003 ± 0.0104 |
| CD3+CD4+fP3+CD25+CD127, Week 8,n=29,27,31,34,25,22 | -0.0006 ± 0.0170 | 0.0055 ± 0.0121 | 0.0004 ± 0.0118 | 0.0055 ± 0.0134 | 0.0003 ± 0.0107 | -0.0000 ± 0.0100 |
| CD3+CD4+fP3+CD25+CD127 Week12,n=25,24,30,34,24,24 | 0.0063 ± 0.0115 | 0.0041 ± 0.0147 | 0.0005 ± 0.0127 | -0.0001 ± 0.0125 | 0.0001 ± 0.0099 | 0.0001 ± 0.0124 |
| T-B cell NKL, Week 4, n=30,32,35,38,29,30 | -0.157 ± 0.5537 | 0.152 ± 0.5655 | -0.051 ± 0.4505 | -0.009 ± 0.4837 | -0.137 ± 0.4446 | -0.083 ± 0.4134 |
| T-B cell NKL, Week 8, n=30,31,33,38,27,26 | 0.057 ± 0.5699 | 0.195 ± 0.5345 | -0.028 ± 0.4384 | -0.064 ± 0.4563 | -0.186 ± 0.4999 | 0.006 ± 0.4809 |
| T-B cell NKL, Week 12, n=27,29,32,36,26,24 | -0.063 ± 0.5793 | 0.163 ± 0.6093 | -0.081 ± 0.4282 | -0.094 ± 0.5229 | -0.193 ± 0.4038 | 0.008 ± 0.4342 |
SBP and DBP were measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Millimeter of mercury (mmHg) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| SBP, Week 1, n=36, 38, 37, 38, 35, 37 | -1.4 ± 10.54 | -0.8 ± 10.54 | 1.6 ± 10.08 | 2.1 ± 6.97 | 1.4 ± 11.18 | 1.1 ± 11.16 |
| SBP, Week 2, n=36, 36, 36, 38, 31, 35 | -2.0 ± 11.61 | -1.0 ± 11.45 | 3.0 ± 10.73 | -0.1 ± 9.79 | 0.6 ± 13.73 | -1.1 ± 13.15 |
| SBP, Week 4, n=32, 34, 35, 38, 29, 31 | 0.4 ± 12.40 | -2.0 ± 12.68 | 2.6 ± 11.54 | -1.4 ± 8.35 | -0.3 ± 13.35 | -0.3 ± 13.22 |
| SBP, Week 8, n=30, 31, 33, 38, 27, 26 | 4.0 ± 12.11 | -1.6 ± 14.25 | 4.0 ± 14.69 | 0.3 ± 13.42 | 0.4 ± 13.34 | 2.4 ± 13.81 |
| SBP, Week 12, n=26, 30, 32, 36, 26, 25 | 3.4 ± 14.09 | -1.5 ± 14.88 | 1.1 ± 12.97 | -0.6 ± 9.51 | 2.0 ± 11.16 | 1.2 ± 12.02 |
| SBP, Week 14, n=29, 31, 33, 34, 27, 26 | -0.3 ± 13.10 | -0.9 ± 14.44 | 2.6 ± 11.66 | -1.1 ± 9.70 | -2.4 ± 15.05 | 2.2 ± 10.97 |
| SBP, EW, n=10, 7, 4, 2, 10, 9 | 5.3 ± 14.73 | 0.4 ± 17.22 | 1.3 ± 8.73 | -10.5 ± 2.12 | -1.3 ± 16.15 | -4.0 ± 13.19 |
| DBP, Week 1, n=36, 38, 37, 38, 35, 37 | 0.9 ± 7.70 | -0.2 ± 7.64 | 0.4 ± 6.61 | 1.5 ± 7.48 | 1.5 ± 10.14 | -0.8 ± 8.27 |
| DBP, Week 2, n=36, 36, 36, 38, 31, 35 | 0.5 ± 8.13 | 0.3 ± 7.55 | 2.3 ± 6.52 | 0.3 ± 7.11 | 1.2 ± 9.51 | 0.0 ± 7.94 |
| DBP, Week 4, n=32, 34, 35, 38, 29, 31 | 1.0 ± 8.04 | 0.7 ± 7.53 | 1.2 ± 6.79 | -0.2 ± 5.77 | -1.8 ± 9.32 | -0.2 ± 7.54 |
| DBP, Week 8, n=30, 31, 33, 38, 27, 26 | 0.1 ± 6.44 | 1.4 ± 9.17 | 2.1 ± 7.26 | 0.9 ± 9.66 | 0.6 ± 8.42 | 0.6 ± 8.18 |
| DBP, Week 12, n=26, 30, 32, 36, 26, 25 | 2.4 ± 9.98 | 1.3 ± 9.00 | 1.0 ± 8.28 | 0.3 ± 8.02 | 0.1 ± 8.60 | -0.1 ± 7.98 |
| DBP, Week 14, n=29, 31, 33, 34, 27, 26 | 0.3 ± 8.80 | 2.5 ± 8.27 | 2.2 ± 5.56 | -0.1 ± 7.64 | -1.1 ± 9.45 | 0.2 ± 9.85 |
| DBP, EW, n=10, 7, 4, 2, 10, 9 | 3.4 ± 6.22 | 1.4 ± 7.32 | 3.5 ± 5.97 | 3.5 ± 16.26 | 1.2 ± 11.49 | -1.1 ± 6.13 |
Pulse rate was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| beats per minute | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=36, 38, 37, 38, 35, 37 | 0.5 ± 8.82 | -0.4 ± 9.40 | 1.7 ± 7.07 | -0.1 ± 9.18 | -0.0 ± 7.65 | -0.6 ± 9.96 |
| Week 2, n=36, 36, 36, 38, 31, 35 | 0.9 ± 10.33 | -3.2 ± 9.77 | 1.4 ± 7.73 | 1.7 ± 9.76 | -1.5 ± 11.51 | 1.6 ± 10.40 |
| Week 4, n=32, 34, 35, 38, 29, 31 | 1.2 ± 8.08 | -0.9 ± 8.08 | 0.8 ± 7.13 | 1.5 ± 9.78 | 2.4 ± 11.14 | -1.7 ± 7.59 |
| Week 8, n=30, 31, 33, 38, 27, 26 | -0.4 ± 8.06 | -0.9 ± 7.59 | 0.2 ± 8.02 | 1.3 ± 9.38 | 2.8 ± 10.54 | 0.2 ± 10.28 |
| Week 12, n=26, 30, 32, 36, 26, 25 | 0.1 ± 9.16 | -2.2 ± 10.18 | 1.4 ± 8.18 | 0.6 ± 9.80 | 1.2 ± 11.75 | 2.6 ± 8.04 |
| Week 14, n=29, 31, 33, 34, 27, 26 | -0.6 ± 8.52 | -0.8 ± 8.27 | 0.2 ± 9.20 | -0.1 ± 8.48 | -0.1 ± 11.14 | 1.3 ± 6.24 |
| EW, n=10, 7, 4, 2, 10, 9 | -2.2 ± 4.54 | -2.7 ± 9.25 | -2.5 ± 5.80 | -4.5 ± 3.54 | 2.4 ± 11.99 | -2.1 ± 7.36 |
Temperature was measured in semi-supine position after at least 5 minutes of rest. Baseline was defined as the latest assessment prior to the first dose and change from Baseline was defined as the value at post dose visit minus the Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| degree Celsius | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Week 1, n=36, 38, 37, 38, 35, 37 | 0.01 ± 0.356 | -0.00 ± 0.336 | -0.03 ± 0.271 | 0.07 ± 0.401 | -0.03 ± 0.548 | -0.03 ± 0.468 |
| Week 2, n=36, 36, 36, 38, 31, 35 | 0.03 ± 0.395 | -0.01 ± 0.410 | -0.01 ± 0.314 | 0.19 ± 0.442 | -0.17 ± 0.473 | 0.03 ± 0.384 |
| Week 4, n=31, 34, 35, 38, 29, 31 | 0.05 ± 0.445 | 0.11 ± 0.385 | 0.06 ± 0.333 | 0.07 ± 0.318 | -0.04 ± 0.405 | 0.03 ± 0.439 |
| Week 8, n=29, 31, 32, 38, 27, 26 | -0.02 ± 0.503 | 0.17 ± 0.334 | 0.12 ± 0.345 | 0.17 ± 0.453 | 0.14 ± 0.473 | 0.11 ± 0.473 |
| Week 12, n=26, 30, 32, 36, 26, 25 | 0.02 ± 0.343 | 0.14 ± 0.423 | 0.12 ± 0.429 | 0.18 ± 0.520 | 0.02 ± 0.492 | 0.12 ± 0.561 |
| Week 14, n=29, 31, 33, 34, 27, 26 | -0.04 ± 0.372 | 0.10 ± 0.364 | 0.01 ± 0.456 | 0.11 ± 0.406 | -0.03 ± 0.522 | 0.00 ± 0.591 |
| EW, n=10, 7, 4, 2, 10, 9 | 0.12 ± 0.466 | -0.09 ± 0.339 | 0.22 ± 0.330 | 0.25 ± 0.778 | 0.30 ± 0.533 | -0.27 ± 0.255 |
The vital signs including SBP, DBP and pulse rate were measured from Baseline throughout the study. The number of participants with clinically significant abnormal vital signs were presented. Baseline was defined as the latest assessment prior to the first dose. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| SBP, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 2 | 0 | 1 | 1 | 0 |
| SBP, Week 1, n=36, 38, 37, 38, 35, 37 | 0 | 1 | 0 | 1 | 0 | 0 |
| SBP, Week 2, n=36, 36, 36, 38, 31, 35 | 0 | 1 | 0 | 0 | 0 | 1 |
| SBP, Week 4, n=32, 34, 35, 38, 29, 31 | 0 | 1 | 0 | 1 | 1 | 0 |
| SBP, Week 8, n=30, 31, 33, 38, 27, 26 | 0 | 0 | 0 | 2 | 0 | 0 |
| SBP, Week 12, n=26, 30, 32, 36, 26, 25 | 1 | 0 | 0 | 1 | 0 | 0 |
| SBP, Week 14, n=29, 31, 33, 34, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP, EW, n=10, 7, 4, 2, 10, 9 | 1 | 1 | 0 | 0 | 0 | 0 |
| SBP, PS, n=n=38, 38, 38, 38, 37, 38 | 2 | 3 | 0 | 2 | 1 | 1 |
| DBP, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 1 | 0 | 0 |
| DBP, Week 1, n=36, 38, 37, 38, 35, 37 | 0 | 0 | 0 | 1 | 0 | 1 |
| DBP, Week 2, n=36, 36, 36, 38, 31, 35 | 2 | 1 | 1 | 0 | 0 | 1 |
| DBP, Week 4, n=32, 34, 35, 38, 29, 31 | 0 | 0 | 1 | 0 | 0 | 1 |
| DBP, Week 8, n=30, 31, 33, 38, 27, 26 | 0 | 1 | 1 | 0 | 0 | 1 |
| DBP, Week 12, n=26, 30, 32, 36, 26, 25 | 1 | 0 | 1 | 2 | 0 | 1 |
| DBP, Week 14, n=29, 31, 33, 34, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP, EW, n=10, 7, 4, 2, 10, 9 | 0 | 1 | 0 | 0 | 0 | 0 |
| DBP, PS, n=38, 38, 38, 38, 37, 38 | 2 | 2 | 1 | 3 | 0 | 1 |
| Pulse rate, Baseline, n=38, 38, 38, 38, 37, 38 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate, Week 1, n=36, 38, 37, 38, 35, 37 | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulse rate, Week 2, n=36, 36, 36, 38, 31, 35 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate, Week 4, n=32, 34, 35, 38, 29, 31 | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulse rate, Week 8, n=30, 31, 33, 38, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate, Week 12, n=26, 30, 32, 36, 26, 25 | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulse rate, Week 14, n=29, 31, 33, 34, 27, 26 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate, EW, n=10, 7, 4, 2, 10, 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate, PS, n=38, 38, 38, 38, 37, 38 | 0 | 1 | 1 | 0 | 1 | 0 |
Single 12-lead ECGs were obtained over a brief recording period at each specified time point during the study using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and corrected QT (QTc) intervals. Baseline was defined as the latest assessment (including unscheduled visits) prior to the first dose. For multiple ECGs at one visit, or "Any time post-screen", a participant is categorized as "Abnormal" if \>=1 assessment is abnormal. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).
| Participants | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Baseline, n=38, 38, 38, 38, 37, 38 | 5 | 8 | 6 | 4 | 6 | 5 |
| Week 1, n=36, 38, 37, 37, 34, 37 | 4 | 8 | 7 | 4 | 5 | 4 |
| Week 12, n=26, 30, 32, 36, 26, 25 | 2 | 6 | 7 | 4 | 4 | 4 |
| Week 14, n=29, 31, 33, 34, 27, 25 | 2 | 5 | 10 | 5 | 2 | 3 |
| EW, n=10, 6, 4, 2, 10, 9 | 1 | 3 | 0 | 0 | 0 | 1 |
| PS, n=38, 38, 38, 38, 36, 37 | 7 | 11 | 10 | 7 | 7 | 7 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment until the Follow up Visit 2 at Week 16.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK2894512 1% BID | 0/38 (0%) | 1/38 (2.6%) | 17/38 (44.7%) |
| GSK2894512 1% QD | 0/38 (0%) | 3/38 (7.9%) | 12/38 (31.6%) |
| GSK2894512 0.5% BID | 0/38 (0%) | 3/38 (7.9%) | 11/38 (28.9%) |
| GSK2894512 0.5% QD | 0/38 (0%) | 0/38 (0%) | 11/38 (28.9%) |
| Vehicle BID | 0/37 (0%) | 0/37 (0%) | 3/37 (8.1%) |
| Vehicle QD | 0/38 (0%) | 0/38 (0%) | 3/38 (7.9%) |
| Event | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/38 | 0/38 | 1/38 | 0/38 | 0/37 | 0/38 |
| Cardiac failure acuteCardiac disorders | 0/38 | 0/38 | 1/38 | 0/38 | 0/37 | 0/38 |
| Coronary artery diseaseCardiac disorders | 0/38 | 1/38 | 0/38 | 0/38 | 0/37 | 0/38 |
| Alcoholic pancreatitisGastrointestinal disorders | 1/38 | 0/38 | 0/38 | 0/38 | 0/37 | 0/38 |
| Enlarged uvulaGastrointestinal disorders | 0/38 | 1/38 | 0/38 | 0/38 | 0/37 | 0/38 |
| Hemolytic uremic syndromeBlood and lymphatic system disorders | 0/38 | 1/38 | 0/38 | 0/38 | 0/37 | 0/38 |
| DehydrationMetabolism and nutrition disorders | 0/38 | 0/38 | 1/38 | 0/38 | 0/37 | 0/38 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/38 | 0/38 | 1/38 | 0/38 | 0/37 | 0/38 |
| Event | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD |
|---|---|---|---|---|---|---|
| FolliculitisInfections and infestations | 8/38 | 2/38 | 4/38 | 5/38 | 1/37 | 0/38 |
| NasopharyngitisInfections and infestations | 1/38 | 0/38 | 4/38 | 2/38 | 0/37 | 2/38 |
| HeadacheNervous system disorders | 4/38 | 1/38 | 0/38 | 1/38 | 1/37 | 1/38 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 4/38 | 4/38 | 1/38 | 3/38 | 0/37 | 0/38 |
| VomitingGastrointestinal disorders | 0/38 | 0/38 | 3/38 | 0/38 | 1/37 | 0/38 |
| Application site dermatitisGeneral disorders | 1/38 | 2/38 | 0/38 | 0/38 | 0/37 | 0/38 |
| AcneSkin and subcutaneous tissue disorders | 2/38 | 0/38 | 1/38 | 0/38 | 0/37 | 0/38 |
| Dermatitis allergicSkin and subcutaneous tissue disorders | 2/38 | 0/38 | 0/38 | 0/38 | 0/37 | 0/38 |
| MiliariaSkin and subcutaneous tissue disorders | 0/38 | 2/38 | 0/38 | 1/38 | 0/37 | 0/38 |
| UrticariaSkin and subcutaneous tissue disorders | 0/38 | 2/38 | 0/38 | 0/38 | 0/37 | 0/38 |
| Age, Continuous(Years) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 45.9 ± 11.93 | 48.5 ± 10.56 | 49.6 ± 10.93 | 48.7 ± 9.72 | 46.7 ± 12.62 | 46.4 ± 10.16 | 47.6 ± 10.99 |
| Sex: Female, Male(Participants) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD | Total |
|---|---|---|---|---|---|---|---|
| Female | 12 | 12 | 14 | 13 | 14 | 9 | 74 |
| Male | 26 | 26 | 24 | 25 | 23 | 29 | 153 |
| Race/Ethnicity, Customized(Participants) | GSK2894512 1% BID | GSK2894512 1% QD | GSK2894512 0.5% BID | GSK2894512 0.5% QD | Vehicle BID | Vehicle QD | Total |
|---|---|---|---|---|---|---|---|
| Race, Customized — American Indian (Amer Ind)/Alaska Native (Ala Nat) | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race, Customized — Asian/South East Asian Descent/Japanese Descent | 10 | 9 | 8 | 6 | 9 | 6 | 48 |
| Race, Customized — Black/African American (Afr Amer) | 1 | 2 | 3 | 1 | 3 | 0 | 10 |
| Race, Customized — White/Caucasian | 26 | 27 | 26 | 30 | 25 | 32 | 166 |
| Race, Customized — Amer Ind/Ala Nat & Black/Afr Amer &White/Caucasian | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race, Customized — Black/Afr Amer & White/Caucasian | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
The record gives a start of Nov 2015, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tapinarof